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ABSTRACT 
 
The efficacy of performing pelvic examinations and Pap smears screening (gynecologic 
screening) in older women has been strongly debated among researchers and policymakers.  
Because of the rare nature of invasive vaginal and vulvar cancers, few epidemiological studies 
have been performed on this group (Mabuchi, et al. 1985, Brinton, et al. 1990a, Brinton, et al. 
1990b) to determine if gynecologic screening reduces the risk of invasive vaginal and vulvar 
cancers.  Previous studies, that have been published, utilized simulated mathematical models and 
small case-control designs to determine the etiology of vaginal and vulvar cancers, rather than to 
determine the efficacy of gynecologic screening.   
This study utilized two large national population-based linked databases: the Medicare 
data set supported by the Centers for Medicare and Medicaid (CMS) and the Surveillance 
Epidemiology and End Results Registries (SEER) data set sponsored by the National Cancer 
Institute (NCI).  The study cases included female Medicare beneficiaries with invasive vaginal 
and vulvar cancers diagnosed between 1991 and 1999 by the SEER Registries (representing 
approximately 14% of the United States population) who were 65 years or over and Medicare 
eligible.  The age and residence matched controls were selected from a five-percent (5%) 
Medicare sample of female beneficiaries 65 years or older, who received care between 1991 and 
1999, had not been diagnosed with cancer, and resided in the SEER areas.  
This matched case-control design utilized incident vaginal (N=328) and vulvar (N=1,103) 
cancer cases, respectively from the Surveillance, Epidemiology and End Results (SEER).  The 
study identified vaginal (N=2,624) and vulvar (N=8,825) cancer controls that were matched on 
age and geographical location to the cases.  This study included women, covered by Medicare, 
who were enrolled in both Parts A and B coverage.  These two matched case-control studies 
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compared cases of persons diagnosed with invasive vaginal or vulvar cancers with non-cancer 
controls who had not been diagnosed with cancer.  The purpose was to investigate whether they 
had a history of gynecologic screening during the estimated combined duration of the pre-
invasive detectable phase (PIDP) when screening is most beneficial, which occurs prior to the 
occult invasive phase (OIP) (Weiss, 1999).    
 Stratified analysis suggested that Pap smear and pelvic examination screenings have a 
stronger negative association among regional (odds ratio (OR) 0.78, 95% CI 0.40-1.51), distant 
(OR 0.31, 95% CI 0.09-1.03) and unstaged (OR 0.86, 95% CI 0.43-1.70) invasive vaginal 
cancers.  Similar findings were observed for vulvar cancers suggesting that gynecological 
screening reduced the risk of regional (OR 0.71, 95% CI 0.51-1.00), distant (OR 0.68, 95% CI 
0.27-1.70) and unstaged (OR 0.77, 95% CI 0.37-1.59) cancer stages.  Borderline significant 
results were observed among women with invasive vaginal distant stage disease, as well as 
invasive vulvar regional stage disease.  These findings suggest that gynecological screening may 
be effective in reducing the risk of later stages of disease of both vaginal and vulvar cancers.  
Women aged 65-74, who had been screened, have a slightly significant decreased risk of vulvar 
cancer (OR 0.55, 95% CI 0.31-0.97).  These findings suggest that screening is most effective in 
reducing invasive vulvar cancer among women aged 65-74 years old.    
 Medicare gynecologic screening may be useful even in women who have had negative 
Pap smear results to reduce the risk of late-stage vaginal and vulvar cancers.  This study was 
unique in that it utilized a larger population-based, matched case-control design that directly 
measured the effectiveness of these secondary prevention measures in women over the age of 65 
years and serves to fill a gap in the current literature. 
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CHAPTER 1: INTRODUCTION 
 
 
 Analyses were performed to determine if the use of gynecologic screening is effective in 
reducing the incidence of invasive vaginal and vulvar cancers in women aged 65 and older; to 
determine whether specific case and matched control subgroups will have unique gynecological 
screening histories based on the progression of disease; and to determine the association between 
gynecological screening test histories and risk of disease by age, race, education, and income 
subgroups.   
Research hypotheses 
H1:   The use of pelvic examination and Pap smear screening is effective in  
reducing the incidence of vaginal and vulvar cancers in women aged 65 and 
older. 
H2: Specific subgroups of cases will have unique screening pelvic examination and 
 Pap smear history relationships based on the progression of disease (i.e., localized, 
regional and distant stages); the more advanced the disease the less likely that the case 
has had sufficient screening. 
H3: There is an association between pelvic examination and Pap smear screenings histories 
and the risk of invasive vaginal and vulvar cancers, which differs by age (using 10-year 
strata), race, education and income of zip code areas. 
Purpose of the study 
The purpose of the study was to determine whether both pelvic examination and Pap 
smear screenings (gynecological screening) decrease the risk of invasive vaginal and vulvar 
cancers in women aged 65 or older using matched case-control designs.   
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The efficacy of performing pelvic examinations and Pap smears screenings in older 
women has been strongly debated among researchers and policymakers.  Because of the rare 
nature of invasive vaginal and vulvar cancers, few epidemiological studies have been performed 
on women who had these invasive cancers (Mabuchi, et al. 1985, Brinton, et al. 1990a, Brinton, 
et al. 1990b).  Previous studies have utilized simulated mathematical models and small case-
control designs to determine the etiology of vaginal and vulvar cancers, rather than investigating 
the effects of screening.   
Rationale 
 The purpose of screening tests is to detect pre-invasive cancers, decrease mortality and 
prevent the development of invasive disease (van den Akker-van Marle, et al. 2002).  Screening 
is designed to detect disease at the preclinical or asymptomatic phase (Wang and Tang, 2010).  
The disease to be screened should have a long preclinical detectible phase; the severity of the 
disease must be considered a burden to the population in terms of disability and death, the 
disease should be be relatively prevalent in the population, and there must be available 
treatments (Wang and Tang, 2010).   
 Vaginal cancer is a rare malignancy that accounts for between one-percent (1%) to three-
percent (3%) of all gynecological malignancies (Creasman, 2005, Tewari, et al. 2001, Tjalma, et 
al. 2001).  Approximately 2,640 new cases of vaginal cancer and 840 deaths occurred last year 
(2011) according to the American Cancer Society (ACS, 2012b).  Furthermore, the incidence of 
invasive vaginal cancer increases at older ages.  The median age at diagnosis is 68 years 
(Howlader, et al. 2012).  
 Vulvar cancer is more common among older women than vaginal cancer. Vulvar cancers 
account for between five-percent (5%) percent and eight-percent (8%) of all gynecological 
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maligancies (Stehman and Look, 2006).   There are estimated to be 4,490 new cases and 950 
deaths for the year 2012 from vulvar cancer (ACS, 2012c).  Similar to vaginal cancer, the 
incidence of invasive vulvar cancer, too, is more often observed at older ages with a median age 
at diagnosis of 68 years (Howlader, et al. 2012). 
 Treatment of both vaginal and vulvar cancers carries side-effects, both short and long 
term.  Vaginal and vulvar cancers may be one of the most difficult types of surgery to cope with 
both emotionally and physically because these genital areas are the most private parts of a 
woman’s body (Cancer Research UK, 2012a , Cancer Research UK, 2012b).   Furthermore, 
many women who are of advanced age with these gynecological cancers may have other 
conditions that interfere with their recovery and may increase long-term chronic health issues 
(Fanfani, et al. 2006, Lagana, et al. 2001). 
Significance of the study 
 
It is well understood that, since the advent of the Pap smear, which generally is 
performed during a routine pelvic examination, the incidence of invasive cervical cancer has 
declined (Waxman, 2005). The Pap smear is a diagnostic laboratory test that is performed to 
detect inflammation, infection, or abnormal cells of the cervix or vagina for the purpose of early 
detection of cervical or vaginal cancers (Fischbach and Dunning, 2004).  A pelvic examination is 
a physical examination of the uterus, vagina, vulva, ovaries, bladder and rectum, the purpose of 
which is to detect cancers, infections, sexually transmitted diseases and other reproductive 
abnormalities (Fetters, et al. 2003).   
 Screening measures, such as pelvic examinations and Pap smears, are an important aspect 
of gynecological health (NCI, 2007).  Screening is especially important for the health of older 
women, because as women age the risk of invasive cancers such as vaginal and vulvar cancers 
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increases (NCI, 2007).  The treatment of invasive disease may include radical surgery, 
chemotherapy, radiation therapy or a combination of therapies, all of which may result in 
disfigurement and sexual disability (Madeleine and Daling, 2006).  The early detection of pre-
invasive vaginal and vulvar cancers, through pelvic examination and Pap smear screening, may 
prevent the development of invasive disease and thereby, prevent the disabling aspects of 
treatment. 
 Based on the preventive nature of these screening protocols, policy recommendations by 
professional and governmental organizations (such as Centers for Medicare and Medicaid 
(CMS)) should be consistent in age recommendations at which to stop screening; however, 
recommendations vary among these organizations.  Based on the rare nature of both invasive 
vaginal and vulvar cancers, few epidemiological studies have been performed to directly 
measure the effectiveness of screening protocols.  Previous studies have utilized simulated 
mathematical models and small case-control designs that estimate the etiology of vaginal and 
vulvar cancers, rather than the preventive nature of screening .  This study is unique in that it has 
a large population-based, matched case-control design that directly measured the effectiveness of 
these secondary prevention measures in women age 65 and older and serves to fill this gap in the 
literature. 
Design and overview of the study 
 This study utilized two large national population-based linked databases: the Medicare 
data set supported by the Centers for Medicare and Medicaid (CMS) and the Surveillance 
Epidemiology and End Results (SEER) data set funded by the National Cancer Institute (SEER-
Medicare, 2003).  The study cases included those women with invasive vaginal and vulvar 
cancers diagnosed between 1991 and 1999 by the SEER Registries (representing approximately 
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14% of the United States population) who were 65 years or older and Medicare eligible.  The age 
and residence matched controls were selected from a five percent (5%) Medicare sample of 
female beneficiaries receiving care between 1991 and 1999 who had not been diagnosed with 
cancer, were 65 years or older and resided in the SEER areas.  
 This study included women, covered by Medicare, who had enrolled in both Parts A and 
B coverage.  This matched case-control design compared cases of persons diagnosed with 
invasive vaginal or vulvar cancers with controls to determine whether they had histories of 
screening during the estimated combined duration of the pre-invasive detectable phase (PIDP), 
which occurs prior to the occult invasive phase (OIP).   
 Conditional logistic regression was used to test the hypothesis that the presence of 
screening is effective in reducing the risk of invasive vaginal and vulvar cancers. Furthermore, 
specific groups of cases (i.e., with localized, regional and distant cancers) were stratified to 
estimate the efficacy of screening for different stages of invasive disease. Stratified regression 
analysis was performed to test the second hypothesis of whether the efficacy of screening varies 
among the various case strata during the OIP/PIDP interval.  The OIP is the phase in which 
abnormal cancer cells have become invasive.  Screening tests are intended to detect abnormal 
cancer cells during the PIDP, not after they have become invasive.  The relationships between 
Pap smear and pelvic examination screenings and the risk of invasive vaginal and vulvar cancers 
was assessed in population subgroups based on strata defined by age, race and educational and 
income level of zip code area. 
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CHAPTER 2: REVIEW OF THE LITERATURE 
 
Introduction 
 Carcinomas of the vagina and vulvar are both rare malignancies.  While vaginal cancer is 
one of the most rare, accounting for approximately one-percent (1%) to three-percent (3%)  of 
gynecological malignancies (Tjalma, et al. 2001, Creasman, 2005, Tewari, et al. 2001); vulvar 
cancer accounts for approximately five (5) to eight (8) percent of all gynecological malignancies 
(Higgins, 2011, Stehman and Look, 2006). Vaginal cancer is generally identified by direct visual 
examination of the vagina and an abnormal Pap smear (Creasman, 2005); while vulvar cancer is 
identified during a routine pelvic examination (Stehman, 1997). 
 The incidence rates for both invasive vaginal and vulvar cancers increase with increasing 
age (Creasman, 2005, Madeleine and Daling, 2006, Ozalp, et al. 2005), which suggest that, on 
the basis of epidemiological data, older women have a higher rate of gynecologic malignancies 
such as endometrium, myometrium, ovary, vulva and vagina, as well as other organ 
malignancies (Ozalp, et al., 2005).  Furthermore, the side effects of invasive cancer treatment can 
be disabling (Quinn, 2007).  This suggests the need for screening protocols specifically for older 
women (previously discussed in Chapter 1: Rationale section).  However, few epidemiological 
studies that directly measure the association between screening tests, such as Pap smears and 
pelvic examinations on vaginal and vulvar cancers, provide useful information in the 
development of consistent screening protocols.   
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Structure of literature review 
 In order to understand the impact of studies and gaps in the literature it is important to 
understand the process by which both vaginal and vulvar cancers develop.  To help explain these 
anomalies, the following literature review will progress as follows: 
 Vaginal cancer 
o Natural history 
o Incidence and mortality 
o Demographic patterns 
o Histopathology and risk factors 
o Symptoms and treatment 
o Prior vaginal cancer research (case-control studies) 
 Vulvar cancer  
o Natural history 
o Incidence and mortality 
o Demographic patterns 
o Histopathology and risk factors 
o Symptoms and treatment  
o Prior vulvar cancer research (case-control studies) 
 Prior research (case-control studies) that relate specifically to both vaginal and vulvar 
cancers 
 Screening 
o Definition and rationale for screening  
o Current policy recommendations for gynecologic screening 
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o Medicare gynecologic screening policies 
o Definition of screening pelvic examinations and Pap smears 
o Mechanism of vaginal and vulvar cancer screening 
o Screening and diagnosis of vaginal cancer 
o Staging of vaginal cancer 
o Screening and diagnosis of vulvar cancer 
o Staging of vulvar cancer 
Vaginal cancer 
Natural history  
 The natural history of vaginal cancer depends on the histologic distinction between 
squamous cell carcinoma and adenocarcinoma since each histologic type has a distinct 
pathogenesis (DiDonato, et al. 2011).  However, the majority of invasive vaginal cancers are 
squamous cell carcinomas (approximately 86%-90%) (Madeleine and Daling, 2006, DiDonato, 
et al. 2011).  Approximately five-percent (5%) of tumors are clear-cell adenocarcinomas that 
have a peak incidence between the ages of 17 and 21 (Madeleine and Daling, 2006, DiDonato, et 
al. 2011).  Clear cell adenocarcinomas are rare and occur most commonly in patients younger 
than 30 years and are associated with vaginal adenosis (DiDonato, et al. 2011).  Vaginal adenosis 
is most commonly arises from maternal diethylstilbestrol (DES) exposure during pregnancy 
(DiDonato, et al. 2011).   Histologic types such as melanomas and sarcomas are rarely 
categorized as primary vaginal cancers (NCI, 2012).   Therefore, these histologic types were not 
included this study’s analysis data set.   
 Squamous cell carcinoma is the most common type of vaginal cancer and primarily 
affects older women (ACS, 2012c).  Squamous cell carcinoma develops in the epithelial lining of 
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the vagina most often in the area closest to the cervix (ACS, 2012c).  This type of cancer may 
exist over a period of many years at a premalignant stage called vaginal intraepithelial neoplasia 
(VAIN) (ACS, 2012c).   
 Squamous cell carcinoma 
In the majority of cases (approximately 85%), vaginal cancer initially spreads superficially 
within the vaginal wall and later invades the paravaginal tissues and the parametria (NCI, 
2012).   In general, squamous cell carcinoma that originates in the epithelial lining of the 
vagina can be localized for many years (Stern, 2011).   Eventually, the carcinoma invades 
the epithelial lining of the vaginal walls (Stern, 2011).  Left untreated, the tumor will spread 
directly to the tissue that surrounds the vagina, the pelvic walls, bladder and/or rectum 
(Stern, 2011).   
 Adenocarcinoma and clear cell adenocarcinoma 
This type of vaginal cancer typically develops in women over the age of 50 (ACS, 2012c).  
Adenocarcinoma is a type of cancer that begins in the epithelial cells that line the vagina and 
have glandular (secretory) properties (Kretschmann, 2002).  This type of adenocarcinoma 
accounts for approximately five-percent (5%) of cases (ACS, 2012c).  The risk factors for 
adenocarinoma in older women may be exposure to the human papillomavirus (HPV) and a 
history of abnormal cells in the cervix (ACS, 2012c). 
Clear cell adenocarcinoma is rare and occurs most often in women who are less than 30 
years old who have a history of maternal diethylstilbestrol (DES) exposure (NCI, 2012).  
The incidence of clear cell adenocarcinoma peaked in the mid-70s, reflecting the use of DES 
in mothers during the 1950s (NCI, 2012).  DES is an oral synthetic non-steriodal estrogen 
that was prescribed to pregnant women at risk for miscarriage between 1938 and 1971 
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(Schrager and Potter, 2004).  The U.S. Food and Drug Administration issued a warning in 
1971 against the use of DES based on new information relating to the association between in 
utero DES exposure and vaginal clear cell adenocarcinoma (Schrager and Potter, 2004).    
Incidence and mortality 
 
 Vaginal cancers are rare and account for only about one-percent (1%) to three-percent 
(3%) of female genital tract malignancies (Creasman, 2005, Tewari, et al. 2001, Tjalma, et al. 
2001).   In 2011, there were approximately 2,640 new cases of vaginal cancers and 840 deaths 
reported (ACS, 2012b).  The median age at diagnosis for cancer of the vagina is 68 years old 
(Howlader, et al. 2012).   The mortality rate from 2005-2009 was 2 per 1,000,000 (Howlader, et 
al. 2012).   
 Demographic patterns 
 Age 
According to the National Cancer Institute, most of the invasive vaginal cancers have been 
observed in older women (NCI, 2012) and the disease is seen most often in women between 
the ages of 60 and 79 (Creasman, 2005).   However, clear cell adenocarcinoma resulting 
from in utero exposure to DES has usually been observed in adolescents after age 14 and has 
a peak incidence at age 19 (Bardawil, 2010).   
 Race 
The 5-year survival rate was 47% for black females compared to 56% for white females 20-
69 years of age (Kosary, 2007a).  The 5-year relative survival was 39.1% for black females 
compared to 41.7% for white females 70+ years of age (Kosary, 2007a). 
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Histopathology and risk factors 
 The most common histological type of vaginal cancers reported to the SEER registries 
are squamous cell in origin (86%), followed by eight-percent (8%) adenocarcinoma, two-percent 
(2%) melanoma and four-percent (4%) other histologies (Madeleine and Daling, 2006).   
 Table 1 describes two models that suggest that vaginal cancer may exist as two separate 
types of cancer.  Type 1 is related specifically to the exposure of DES, while Type 2 is squamous 
cell in origin.  The exposure of DES in utero is a known risk factor for clear-cell adenocarcinoma 
that is typically found in younger women (Bardawil, 2010, Schrager and Potter, 2004).  
Offspring of pregnant women who took DES during pregnancy are at a higher risk of developing 
vaginal cancer, particularly clear cell adenocarcinoma (Schrager and Potter, 2004).   Clear cell 
adenocarcinoma was most likely to develop in women with in utero DES exposure after age 14, 
and peak incidence is at age 19 (Bardawil, 2010).  Since the focus of this study was on women 
who are over the age of 65, it is likely that there will be very few women with clear cell 
adenocarcinoma due to DES exposure in this study.   
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Table 1. Types of vaginal cancer 
Characteristic   Type 1     Type 2 
Age    Younger (after age 14 and peak  Older (Average ~68) 
    incidence at age 19 years) 
 
Cervical neoplasia  High association    High association 
 
Cofactors   DES exposure    Increasing age 
 
Histopathology of tumor  Clear cell adenocarcinoma   Squamous cell carcinoma 
 
HPV DNA   No association    Frequent (> 60 percent) 
 
Pre-existing lesion  CIN/VAIN/adenosis   CIN/VAIN 
 
History of condyloma  Rare association    Strong association 
 
History of sexually trans-   
  mitted disease (STD)  Rare association    Strong association 
 
Cigarette smoking  Low prevalence    High prevalence 
 
Number of sexual 
  partners   No association    Strong association 
 
Previous abnormal 
 Pap smear   Strong association   Strong association 
 
Prior hysterectomy  No association    Strong association 
 
Vaginal trauma 
  (pessary use)   No association    Strong association 
 
Vaginal adenosis   DES exposure    No association  
  
  
 
 The following are explanations of each of the risk factor characteristics as described in 
Table 1. 
 Cervical neoplasia 
 
A history of prior dysplasia or invasive carcinoma of the cervix has been reported in 
approximately 30% of patients with vaginal carcinoma (Hellman, et al. 2004).  Vaginal and 
cervical carcinomas have etiologies in common (Hellman, et al. 2004).  The vagina and the 
cervix are lined with the same type of squamous cell epithelium and are embryologically 
13 
 
related (Hellman, et al., 2004).  The major difference between vaginal and cervical 
carcinoma is that they occur in different age groups.  Cervical carcinoma mainly occurs in 
women younger than 60, while vaginal carcinoma occurs mainly in older women (Hellman, 
et al. 2004).   
 HPV DNA 
Oncogenic HPVs have been strongly associated in the development of squamous cell 
carcinoma of the vagina (Type 2) (Hellman, et al. 2004, Feng and Kiviat, 2005, Bardawil, 
2010, Daling, et al. 2002, Hildesheim, et al. 1997b, Jamieson, et al. 2006).  According to 
Bardawil (2010), the two types with the highest oncogenic potential are HPV subtypes 16 
and 18, and infection with these subtypes can be linked to dyplastic changes in the female 
genital tract (Bardawil, 2010).   
 Number of sexual partners 
Sex with multiple partners may be a risk factor for the disease since HPV is a sexually 
transmitted disease (Bardawil, 2010, Brinton, et al. 1990b).   
 Abnormal Pap smear 
In general, an abnormal vaginal Pap smear in women who have not had a hysterectomy is 
usually vaginal neoplasia (Creasman, 2005).  However, an abnormal Pap smear is usually an 
indication of possible neoplasia of the cervix rather than vagina, although studies have 
suggested CIN can extend to the vagina (Creasman, 2005).  Vaginal intraepithelial neoplasia 
(VAIN) is usually located in the upper third of the vagina and more than half to two-thirds 
of all patients with VAIN have been treated for either cervical or vulvar neoplasia 
(Creasman, 2005).  Furthermore, for patients who have been treated for cervical neoplasia, 
VAINs can appear many years later (Creasman, 2005).   An increased risk for vaginal cancer 
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exists among women with two or more abnormal Pap smears (Brinton, et al. 1990b).   A 
history of abnormal Pap smears was found among HIV-infected women with vulvar, vaginal 
or anal intraepithelial neoplasia (Jamieson, et al. 2006). 
 Smoking 
Cigarette smoking places women at increased risk for vaginal cancer (Greene, et al. 2002). 
 Condyloma 
There are more than 40 HPV types that affect the genital areas of both males and females.  
While most condyloma or genital warts are associated with HPV Types 6 and 11 that  are 
associated with vaginal cancer, there may be other subtypes that contribute both condyloma 
and the development of vaginal cancer (such as high risk HPV types 16 and 18) (Nuovo, 
2006). 
 Prior hysterectomy 
The risk for vaginal carcinoma is highest in women who had a prior hysterectomy before the 
age of 40 (Brinton, et al. 1990b).  The association between primary vaginal carcinoma and 
hysterectomy might be due to ambiguous surgical margins occurring with residual CIN or 
occult disease (Hellman, et al. 2004).  In patients who have had a hysterectomy for benign 
disease, a subsequent Pap smear screening may not be beneficial based on the rare nature of 
vaginal cancer (Creasman, 2005).  However, primary vaginal neoplasia does occur more 
frequently among women with prior hysterectomy for benign disease and is more common 
today than several decades ago (Creasman, 2005). 
 Vaginal trauma (pessaries use) 
Pelvic organ prolapse affects 50% of parous women over the age of 50 (Fernando, et al. 
2006).  The treatment for pelvic organ prolapse has included non-surgical procedures such as 
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pelvic floor exercises and vaginal pessaries (Fernando, et al. 2006).  One study of cancer and 
pessary use conducted by Schraub, et al. (1992) found that pessaries had been used by 30% of 
vaginal carcinoma cases.  Furthermore, long-term pessary use and chronic irritation of vaginal 
mucosa in women with procidentia (complete failure of genital supports) has been associated 
with vaginal cancer (Bardawil, 2010). 
 Vaginal adenosis 
Vaginal adenosis is a specific abnormality of the vagina (ACS, 2012c).  Women affected are 
those who mothers took diethylstilbestrol (DES) during pregnancy.  DES was a hormone used 
to prevent miscarriage in the U.S. from the years 1950 until 1971 (ACS, 2012c). 
Symptoms and treatment 
 The most common signs and symptoms of invasive vaginal cancer include:  
 vaginal discharge (often bloody) which is the most frequent symptom (Stehman, 1997) 
 irregular or postmenopausal vaginal bleeding (Stehman, 1997) 
 gross lesion (detected via pelvic examination) (Stehman, 1997) 
 urinary symptoms (vaginal cancer can result in compression of the bladder, usually during 
the early stages of disease) (Stehman, 1997) 
 The elasticity of the upper vaginal area allows for large lesions to grow, which may not 
be detected, especially in women who are not sexually active (Stehman, 1997).  These lesions are 
usually detected during late stages of the disease possibly because many patients are older 
women, sexually inactive and less likely to have routine pelvic examinations.  In addition, the 
diagnoses may be delayed by virtue of the rare nature of the disease, as well as a possible delay 
in relating symptoms to vaginal cancer (Bardawil, 2010).    
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 The treatment of invasive vaginal cancer depends on the histologic type, stage,       
location of the lesion, presence or absence of the uterus and history of previous radiation therapy 
(Bardawil, 2010, Stehman, 1997).  Treatment consists of radiation therapy, surgery, 
chemotherapy or a combination of these treatments (Bardawil, 2010).   In general, however, 
stage IVa treatment consists of both radiation therapy and pelvic exenteration (radical surgery 
that removes all organs from the pelvic cavity) (Bardawil, 2010).  Pelvic exenteration is 
performed if a rectovaginal (abnormal connection between the rectum and vagina) or 
vesicovaginal (abnormal connection between the urinary tract and the vagina) fistula is present 
(Bardawil, 2010).   If surgery for stage IVb cancer is not recommended, then radiation therapy is 
recommended for the palliative purposes only (relief of symptoms) (Bardawil, 2010).     
Case-control studies 
The purpose of Brinton, et al. (1990b)'s study was to investigate a pattern of risk for those 
cases with in situ and invasive vaginal carcinoma and shared etiology with cervical cancer.  The 
cervical cancer risk factors included reproductive and sexual factors, selected hygiene factors, 
Pap smear screening history, selected medical conditions (sexually transmitted diseases and 
previous cervical cancer diagnosis), menopause status, oral contraceptive use and smoking 
status.   
The study consisted of 41 pathologically confirmed cases diagnosed with in situ or 
invasive vaginal cancer and 97 controls.  The cases ranged in age from 20 to 79 years, while the 
controls ranged in age from 20 to 69 years.  Efforts were made to match at least two controls of 
the same age (within 5 years), race and area of residence to one case. 
All of the cases reported having a Pap smear at least one year before diagnosis and all but 
four controls reported a previous Pap smear.  Of particular interest to this study, the findings did 
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not suggest whether the presence of screening was effective in reducing vaginal cancer (i.e., all 
the cases had a previous Pap smear).  However, a significant increased risk was found among 
subjects with two or more abnormal Pap smears (RR 6.7, 95% CI 1.8-25.9) even after cases with 
a history of cervical cancer were eliminated and risks were adjusted for type of cancer and age at 
menopause. 
The low response rate (48.2% of cases and 57.1% of controls agreed to participate in the 
study) may not have allowed the researchers to stratify on age.  Another important aspect would 
have been the examination of the relationship of in situ and invasive vaginal cancer to specific 
risk factors such as Pap smear history. 
The purpose of Daling, et al. (2002)'s population-based, case-control study was to 
investigate the etiology of in situ or invasive squamous cell cancer of the vagina and the potential 
relationship to HPV.  The study included 156 cases and 2,041 controls between the ages of 18 
and 74 years.  Interviews of cases and controls were conducted that included demographic, 
reproductive, contraceptive, medical, sexual and smoking histories.  In addition, blood samples 
were requested at the end of the interview and 94.2% of cases and 89.5% of controls consented.  
Tumor blocks were also requested of cases for HPV testing; 67.9% cases consented to testing.   
 The results of the study suggest that HPV negative cases were found more frequently 
among somewhat older women, further supporting the hypothesis that HPV DNA may not be a 
critical risk factor in the development of invasive vaginal cancer among older women (Table 1).  
Furthermore, in situ tumors were more common among younger women; while invasive vaginal 
cancer was more common among older women.  During the interview process, subjects were 
asked about abnormal Pap smear history.  Among women who had a previous hysterectomy, but 
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no history of anogenital cancer, 75.5% had an abnormal Pap smear history compared to 18.1% of 
similar controls.   
 The limitations of the study include the low participation rate among both cases and 
controls.  Of the 256 potential cases, 156 were interviewed for a 58.9% response rate (51 refused, 
30 physicians refused and 28 women died).  Of the 2,784 potential controls, 2,041 (67.7%) 
agreed to participate in the study.  In addition, the measure of HPV exposure was limited to HPV 
16 and HPV 18 subtypes only.  There were other oncogenic HPV subtypes there were not 
investigated.  Another limitation of interest to this study is that, while some Pap smear histories 
were taken, they were restricted to women who had previous hysterectomies.  The study was not 
able to perform stratified analyses by age due to the small number of cases.   
The study conducted by Hildesheim, et al. (1997b) tested the serologic response to 
HPV16 VLPs, HSV2 and c. trachomatis and risk of carcinoma of the vagina.  The case-control 
study included 23 histologically confirmed cases of in situ or invasive vaginal cancer and 28 
controls.  Both cases and controls ranged in age from 20 to 79 years.  In-person interviews were 
also conducted to collect data on risk factors such as socioeconomic status, a history of an 
abnormal Pap smear and a previous diagnosis of cervical cancer.   
The results of the Hildesheim, et al. (1997b)'s study suggest that the greatest risk was 
among subjects with high levels of antibodies against HPV16 VLP (RR 33.0, 95% CI 2.5-430) 
and for those positive for evidence of infection with all three antibody sexually transmitted 
agents (RR 17.0, 95% CI 1.3-220).  After adjustment for HSV2 and c.trachomatis, the increased 
HPV16 VLP associated risk was not reduced (RR 3.4. 95% CI 0.79-15).  However, risk was 
reduced for HSV2 and c. trachomatis after adjusting for the two other sexually transmitted 
agents (RR 2.1, 95% CI 0.31-14 and RR 1.7, 95% CI 0.34-8.4, respectively). 
19 
 
Even though the results were statistically significant, this study was limited by the small 
sample size (23 cases and 28 controls).  Risk in different age strata was not described, possibly 
due to the small sample size.  Furthermore, Pap smear and pelvic examination histories were not 
reported. 
Summary of case-control studies 
 The case-control studies described above were conducted primarily to investigate the 
etiology of vaginal cancer (Table 2).  Overall, the conclusions suggest that the risk of invasive 
vaginal cancer is increased among women who report a history of abnormal Pap smears 
(Brinton, et al. 1990b, Daling, et al. 2002).   In addition, both Daling, et al. (2002) and 
Hildesheim (1997b) found oncogenic HPV DNA to be a risk factor among women with invasive 
vaginal cancers; however, Daling et al. (2002), suggests that the risk is increased only among 
young women and that HPV negative cases are found primarily among older women.  
Hildesheim (1997b) was unable to report stratified data by age due to the very small sample, 
thereby the findings do not provide this study with similar results as the Daling, et al. (2002) 
study.  Furthermore, these studies also had small sample sizes and the prevention measures such 
as Pap smears and pelvic examination histories were not reported in all of the studies.   
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Table 2. Vaginal cancer: case-control studies 
 Diagnosis year Study Cases Controls Purpose Age 
Brinton, Nasca, Mallin, Schairer, Rosenthal, 
Rothenberg, Yordan and Richart (1989) 
1986 Case-control 
 
41 97 Types of vaginal 
cancer 
20-79 
       
Daling, Madeleine, Schwartz, Shera, Carter, 
McKnight, Porter, Galloway, McDougall, 
Tamimi (2002) 
1991-1998 Case-control 156 2,041 Etiology of 
vaginal cancer 
18-74 
    
Hildesheim, Brinton, Nasca, Richarts, 
Jones, Ziegler and Schiller (1997b) 
1985-1987 Case-control 23 28 Sexually transmitted 
agents 
20-79 
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Vulvar cancer 
Natural history 
 The etiology of vulvar cancer depends on the histologic subtype (squamous cell carcinoma 
and basal cell carcinoma) (Stehman and Look, 2006).  The majority (90%) of vulvar cancer tumors 
are squamous cell carcinomas (Canavan and Cohen, 2002).  Melanomas, sarcomas, basal cell 
carcinomas, Bartholin gland carcinomas, adenocarcinomas and undifferentiated histologies, are the 
other histological subtypes (Stehman, 1997). 
 Squamous cell carcinoma 
There are different subtypes of squamous cell carcinoma of the vulva, one that is associated 
with HPV and one that is not (Stehman and Look, 2006).  The vulvar intraepithelial neoplasia 
(VIN) that arises from HPV exposure predisposes women to invasive disease (Canavan and 
Cohen, 2002).  This type most frequently occurs among younger women (Canavan and Cohen, 
2002).  Conversely, the second type that is not HPV related is associated with  vulvar non-
neoplastic epithelial disorders (VNED) and occurs at older ages leading to cellular atypia and 
cancer (Canavan and Cohen, 2002).   
 Basal cell carcinoma 
Most of the vulvar cancers that appear in younger women arise in a field of warty or baseloid 
VIN and approximately 80% of those with warty VIN develop invasive disease (Canavan and 
Cohen, 2002).  
 Paget disease 
Paget disease is primarily a disease of older post-menopausal women and most prevalent in 
whites (Wilkinson and Stone, 2008). 
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Incidence and mortality 
 Vulvar cancers are not as rare as vaginal cancers and account for approximately five-percent 
(5%) to eight-percent (8%) of all gynecological malignancies (Stehman and Look, 2006).   There are 
estimated to be 4,490 new cases, and 950 deaths for the year 2012 from vulvar cancer (ACS, 2012a).  
The median age at diagnosis for vulvar cancer is 68 years (Howlader, et al., 2012).  
 The mortality rate 2005-2009 was 5 per 1,000,000 (Howlader, et al. 2012).  However, 
mortality rates increase as age increases.  For patients younger than 20, none of the patients died 
from vulvar cancer (Howlader, et al. 2012).  Deaths for patients between the ages of 20 and 34 was 
0.6%, ages 35 and 44, 2.4%, ages 45 and 54, 12.0%, ages 55 and 64, 17%, between 65 and 74, 
30.8% and 85 and over 29.8% (Howlader, et al. 2012).   
Demographic patterns 
 Age 
 
While vulvar cancer has been observed in young women (approximately 15%) it is most 
commonly observed among women who are in their seventies (approximately 30%) (Stehman 
and Look, 2006), and the rate increases with age, reaching a peak of 20 per 100,000 women by 
75 years of age (Canavan and Cohen, 2002).   
 Race 
 
The 5-year relative survival rate was 81.6% for black females compared to 81.4% for white 
females 20-69 years of age (Kosary, 2007b).  The 5-year relative survival rate was 59.9% for 
black females compared to 66.5% for white females 70+ years of age (Kosary, 2007b).   
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Histopathology and risk factors 
 
The SEER registries report that most vulvar cancers are 92% squamous cell followed by two-
percent (2%) basal cell, two-percent (2%) melanoma, two-percent (2%) Paget’s disease and two-
percent (2%) “other” histologies (Madeleine and Daling, 2006).    
Canavan and Cohen (2002), suggest that squamous cell vulvar cancer may be two separate 
types of cancer as illustrated in Table 3.  Warty, basaloid or keratinizing patterns characterize 
squamous cell vulvar cancer (Madeleine and Daling, 2006).  Type 1 is warty or basaloid and tends to 
be due to infection with oncogenic HPV (Madeleine and Daling, 2006, Canavan and Cohen, 2002).  
An estimated 80% of younger women with warty or basaloid vulvar intraepithelial neoplasia (VIN) 
who remain untreated will develop invasive disease (Canavan and Cohen 2002).   
Type 2, keratinizing vulvar cancer, on the other hand, has an undifferentiated morphology 
(Canavan and Cohen 2002).  This type includes vulvar non-neoplastic epithelial disorders (VNED) 
and is observed at an advanced age (Canavan and Cohen, 2002).  This type is not associated with 
HPV infection and often appears with lichen sclerosus or epithelial hyperplasia leading to cellular 
atypia and cancer (Madeleine and Daling, 2006, Canavan and Cohen, 2002).  
Table 3 describes the etiology of the two types of vulvar cancer. 
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Table 3. Types of vulvar cancer 
Characteristic    Type 1    Type 2 
Age    Younger (35 to 65 years old)  Older (55 to 85 years old) 
 
Cervical neoplasia  High association    Low association 
 
Cofactors   Age, immune status,    Vulvar atypia, possibly 
    viral integration    mutated host genes 
 
Histopathology of tumor  Intraepitelial-like (baseloid)  Keratinizing; squamous cell 
         carcinoma 
 
HPV DNA   Frequent (> 60 percent)   Seldom (< 15 percent) 
 
Pre-existing lesion  VIN     Vulvar inflammation, lichen  
         sclerosus, squamous cell 
         hyperplasia 
 
History of condyloma  Strong association   Rare association 
 
History of sexually trans-  
  mitted disease (STD)  Strong association   Rare association 
 
Cigarette smoking  High incidence    Low incidence 
 
Number of sexual 
  partners   Strong association   Low association 
 
Previous abnormal 
  Pap smear   Strong association   Strong association  
 
 Prior history of cervical cancer 
Jones and Rowland (2009) suggest that women who have previously been treated for pre-
invasive or invasive disease in the cervix or vagina have an increased risk of developing 
invasive vulvar cancer. 
 Human papillomavirus (HPV) 
HPV has been strongly associated in the development of squamous cell carcinoma of the vulva 
(Madeleine, et al. 1997, Jones and Rowland, 2009).   There are etiologic pathways leading to the 
development of vulvar cancer that do not involve HPV, especially among older women 
(Madeleine, et al. 1997).  Judson, et al. (2006) suggest that there are different age distributions 
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for invasive vulvar and cervical cancers, particularly in combination with patterns of in situ 
disease, which suggests that factors other than HPV are related to the development of invasive 
vulvar cancer especially in older women.  The Basta, et al. (1999) study finds statistically 
significant results in women under the age of 45 with respect to HPV and non-significant 
findings among women over age 45 years. 
 Number of sexual partners 
Brinton, et al. (1990a) suggests that an increasing number of sexual partners increase the risk of 
invasive vulvar carcinoma.  
 History of abnormal Pap smear 
Patients with a history of abnormal cervical cytology have an increased risk of invasive vulvar 
carcinoma (Stehman and Look 2006, Jones and Rowland 2006). 
 Smoking 
Cigarette smoking is associated with increased risk of vulvar carcinoma (Stehman and Look, 
2006, Madeleine, et al. 1997, Brinton, et al. 1990a).  Mabuchi, et al. (1985), conducted a case-
control study of the epidemiology of vulvar cancer and ascertained smoking habits and found 
that among current smokers, a significantly increased OR (2.46, p<0.05) was obtained for 
individuals smoking ten (10) to 20 cigarettes per day.      
 Condyloma  
Women with a history of condyloma, gonorrhea and HSV have an increased risk of both 
carcinoma in situ and invasive vulvar carcinoma (Stehman and Look, 2006, Jones and Rowland, 
2006). A case-control study, conducted by Mabuchi, et al. (1985) with 149 cases with 
histologically confirmed vulvar carcinoma and the same number of patient controls without 
vulvar cancer that were matched for age, race, marital status and hospital from five (5) U.S. 
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metropolitan areas, suggested that condyloma or genital warts was present in five-percent (5%) 
to 10% of vulvar cancer cases.  
Symptoms and treatment 
 The most common symptoms of invasive vulvar cancer are: 
 chronic, persistent itching (ACS, 2012a) 
 distinct tumor on the vulva   
 painful urination, bleeding and discharge not associated with normal menstruation   
 ulcer that persists for more than a month (ACS, 2012a, Stehman, 1997) 
 Many of these symptoms can occur with other conditions; therefore, sometimes practitioners 
fail to recognize the presence of invasive vulvar carcinoma (ACS, 2012a). 
 The type of treatment depends on histology, stage and location of the lesion (e.g., whether 
bowel or bladder involvement exists) (ACS, 2012a).  Early stage disease treatment options include 
laser surgery, wide local excision or a skinning vulvectomy (a little thicker amount of skin is 
excised) (ACS, 2012a).  However, even in stages I and II vulvar cancer treatment options include a 
partial radical vulvectomy, which includes the removal of superficial and deep groin lymph nodes or 
sentinel node biopsy (sentinel nodes are the lymph nodes to which cancer cells are likely to spread 
from the primary tumor) (ACS, 2012a).  Stage III includes a radical vulvectomy with removal of 
lymph nodes (ACS, 2012a).  However, recently, therapeutic options also include combination 
therapies, such as chemotherapy and radiation therapy, followed by surgery (ACS, 2012a).   
 Later stage disease (stage IV) includes a radical vulvectomy and other surgery (dependent on 
the metastases to other organs), such as pelvic exenteration that includes a vulvectomy and removal 
of the pelvic lymph nodes and one or more organs (lower colon, rectum, bladder, uterus, cervix and 
vagina) (Higgins, 2011).  Chemotherapy may be required pre-surgery and radiation therapy may be 
required post-surgery (Higgins, 2011).  Surgery may not be advised (based on the size of the tumor 
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and organ involvement) and radiation and chemotherapy may be the preferred treatment option 
(Higgins, 2011).   In this case, chemotherapy and radiation therapy may be prescribed to treat 
symptoms (palliative care), not for curative purposes (Higgins, 2011).  Women with late stage (stage 
IV) vulvar cancer are encouraged to enter clinical trials where they may receive new therapies that 
may be beneficial (ACS, 2012a).  The five-year survival rate for women with late stage (stage IV) 
vulvar cancer is only 20% (Higgins, 2011).   
Case-control studies 
The case-control study by Basta, et al. (1999), collected Pap smears to obtain specimens from 
the vulva and performed a colposcopic examination of the cervix, vagina and vulva in all cases of 
vulvar intraepithelial neoplasia (VIN) and early stage vulvar cancer.  The study investigated the role 
of HPV types 6, 11, 16, 18, 25, 31, and 33 in the development of VIN and early stage vulvar cancer 
(Basta, et al. 1999).  Pap smears were also used to obtain specimens from 178 cases (68 women 
under the age of 45 and 110 women over the age of 45) from the vulva and a colposcopic 
examination of the cervix, vagina and vulva was also performed.  The 115 controls (between the 
ages of 24 and 76) were both colposcopically and cytologically negative.     
However, in accordance with the vulvar cancer model presented in this study (Table 3), the 
relative risk (RR) for VIN and VIN1 showed a statistically significant increased risk in women under 
45 years old associated with HPV infection (RR 11.34, p<0.001), and non-significant results for 
women over 45 years (RR 1.43).  HPV infection is less strongly associated with vulvar cancer in 
older women than in younger women.  While the study utilized Pap smears and other evaluation 
techniques, neither histories of previous Pap smears nor pelvic examination histories was 
investigated. 
The Brinton, et al. (1990a), Parazzini, et al. (1993) and Sherman, et al. (1994), studies 
collected information relative to Pap smear histories via interview to test their hypotheses.  The 
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Brinton, et al. (1990a)'s study was designed to investigate the etiology of carcinoma of the vulva.  
Risk factors investigated included measures of sexual behavior, menstrual, reproductive and hygiene 
factors, smoking history, contraceptive methods, history of sexually transmitted diseases and 
selected risk factors such as number of sexual partners, Pap smear history, genital wart history and 
current smoking status.  The study group consisted of 209 pathologically confirmed cases of women 
with in situ or invasive vulvar cancer and 348 controls, matched on age (within 5 years), race and 
residence.  The ages of the cases ranged from 20 to 79 years, while the control ages ranged from 20 
to 69 years.  
Of particular interest to this study (Osterbur’s), Brinton, et al. (1990a) further examined the 
relationship of in situ and invasive disease to specific risk factors such as number of sexual partners, 
Pap smear history, genital wart history and smoking status.  The relative risk of in situ vulvar cancer 
was greatest for cases who had between five to nine sexual partners (RR 5.08, 95% CI 1.7-14.8), 
ever had genital warts (RR 18.50, 95% CI 5.5-62.5) and current smoker (RR 4.65, 95% CI 2.2-10.0) 
(Brinton, et al. 1990a).  The relative risk of invasive vulvar cancer was greatest for cases that had 
between three and four sexual partners (RR 3.32, 95% CI 1.6-7.1), no previous Pap smear (RR 2.46, 
95% CI 0.9-6.7) and ever had genital warts (RR 14.55, 95% CI 1.7-125.6).   
While this study found an association between the absence of previous Pap smears (RR 2.46, 
95% CI 0.9-6.7) and invasive vulvar cancer, the small sample size of the study population may not 
have allowed researchers to report on age strata or the frequency of Pap smear screening.   
The purpose of Parazzini, et al. (1993)'s study was to evaluate the risk factors for invasive 
vulvar cancer.  The study included 73 cases with histologically confirmed invasive vulvar cancer and 
572 hospital controls in Milan, Italy.  The cases ages ranged from 41 to 74 years old and controls 
ranged in age from 38 to 74 years old.   Both cases and controls provided information such as 
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demographic variables, lifestyle habits, gynecological and obstetric data, related medical history, 
sexual habits and lifetime histories of Pap smears.   
 The main findings of the study include the inverse relationship of education level and 
invasive vulvar cancer (RR 0.6 and RR 0.4, respectively for subjects reporting seven (7) to 11 and 12 
years or more of education).  A higher risk existed among overweight women, but the trend was not 
statistically significant after taking into account confounding factors.  There was a 70 to 80 percent 
lower risk of invasive vulvar cancer among women reporting ever having a Pap smear than in 
women reporting never having a Pap smear.  
 This study also stresses, from a public health perspective, the importance of Pap smear 
screening.  Furthermore, the study suggested that Pap smear screening is largely associated with 
pelvic examination and has preventive implications regarding the importance of cervical screening 
programs for older women.  This is of particular interest to this study, since some studies take into 
account the Pap smear status, while the pelvic examination status is often ignored even though these 
procedures generally occur together.  The major limitation to this study is the small sample size.  Of 
value is its provision of data for comparison with the American studies. 
The purpose of Sherman, et al. (1994)’s case-control study was to determine if the 
reproductive history, menstrual history, exogenous estrogen use and body mass may play a role in 
the etiology of vulvar cancer.  The study sought to determine the relationship with hormonal factors 
in vulvar cancer and utilized an interview process but did not obtain Pap smear or pelvic 
examination histories. 
The study included 330 cases and 1,010 controls aged 18 to 79 years old (Sherman, et al. 
1994).  The results suggested that women diagnosed with vulvar cancer were at slightly higher risk 
due to early menarche [(before age 12) (OR 1.8, 95% CI 1.2-2.7), in situ cancer (OR 1.6, 95% CI 
0.8-3.1)], excess weight (invasive cancer only, OR 2.9, 95% CI 1.5-5.8 for highest tertile of 
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Quetelet’s index (body mass index)) and among pregnant women who have had their first pregnancy 
after age 24 (in situ only, OR 1.5, 95% CI 0.9-2.5).  These findings suggest that in situ and invasive 
vulvar cancers are not strongly hormone related. 
 Limited information was provided concerning Pap smear history (results were not reported) 
which would have been of interest to this study.  In addition, age strata were not provided that might 
have suggested the impact of invasive vulvar cancer on older women.   
Madeleine, et al. (1997)’s study collected tissue samples from tumor blocks and sera to 
determine risk factors in the etiology of vulvar cancer.  The purpose of the Madeleine, et al. (1997)'s 
matched case-control study was to determine the association of HPV, cigarette smoking and/or 
HSV2 with vulvar cancer.  The study included 510 cases of in situ and invasive vulvar cancers with 
1,403 controls of women between the ages of 18 and 79 years.   
Interviews of cases and controls were conducted to collect demographic information, 
reproductive, birth control, sexual and smoking histories.  The controls were frequency matched to 
the age distribution of cases in 5-year intervals.   Furthermore, blood samples were requested from 
all subjects to which 479 (93.9%) cases and 1,215 (86.6%) controls consented.  Tumor blocks were 
also requested from case subjects.  HPV seropositivity to HPV 6, 16 and 18 was determined by the 
use of an ELISA test of all study samples.  Antibody response to HSV2 was determined by the use 
of the Western Blot on all study samples.  Vulvar tumor tissue was classified with respect to the 
presence or absence of HPV positivity through the use of polymerase chain reaction (PCR) to 
amplify HPV DNA.  A board-certified pathologist reviewed the histological slides of 34 cases of 
invasive vulvar cancer. 
The results of the study indicate that over half (51.8%) of cases who had invasive vulvar 
cancer were age 60 or over.   Furthermore, the findings suggest that in situ tumors were more 
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common among younger women.  The subjects who had two or more sexual partners or first 
intercourse before age 17 were more common among cases than controls.   
Additional results suggested by Madeleine, et al. (1997) show the OR associated with 
HPV16 positivity for in situ tumors was 3.6 (95% CI 2.6-4.8) and for invasive vulvar cancer was 2.8 
(95% CI 1.7-4.7).   Smoking for in situ was 6.4 (95% CI 4.4-9.3) and for invasive cancers it was 3.0 
(95% CI 1.7-5.3).  The OR associated with HPV16 positivity and never smoking was 2.9 (95% CI 
1.7-5.0); current smoking and HPV16 negativity was 4.9 (95% CI 3.3-7.5) and current smoking and 
HPV16 positivity was 18.8 (95% CI 11.9-29.8).   
The OR associated with HSV2 positivity and HPV16 negativity was 1.9 (95% CI 1.3-2.7); 
HSV2 negativity and HPV16 positivity was 3.2 (95% CI 2.2-4.9) and HSV2 and HPV16 positivity 
was 5.7 (95% CI 3.8-8.4).  In addition, among 34 case subjects registered as having invasive 
squamous cell tumors, histological slides were obtained.  Of the 34 cases, 76.5% (26) were classified 
as keratinizing squamous cell carcinoma and 23.5% (8) were classified as basaloid or warty 
carcinoma.  In 75% of the basaloid or warty carcinomas and 22.7% of keratinizing squamous cell 
carcinoma HPV 16 DNA was found.   
The limitations of the study include the small sample size for both cases and controls 
(Madeleine, et al. 1997).  Another limitation was that in the subset of invasive cancers, only 34 of 
the 110 were reviewed by a pathologist.  There was also a lack of HPV DNA tissue testing among 
controls suggesting that the prevalence of HPV DNA may be underestimated.   There may be other 
oncogenic HPV types not investigated in this study (the study tested HPV 6, 16 and 18) that are 
important in the natural history of vulvar carcinoma.   
Other limitations are that pelvic examination and Pap smear histories were not investigated 
and the analyses were not stratified by age or the presence of HPV DNA.  Other studies have 
hypothesized that invasive cancers in older women are not HPV related.   
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The matched case-control study conducted by Trimble, et al. (1996) collected abnormal Pap 
smear histories via interview as part of the study to estimate risk factors in the etiology of squamous 
carcinoma of the vulva.  The study included 123 cases histologically confirmed squamous 
carcinomas of the vulva between the ages of 20 and 70 years and 246 controls.  Two (2) controls 
were matched to one (1) case on age, race and residence.  
The purpose of the study was to evaluate the risk factors, histological types and presence of 
HPV in squamous carcinoma of the vulva.  Interview data was available from 71 of the 123 cases.  
Both cases and controls responded to a detailed questionnaire to obtain information on risk factors 
for vulvar cancer such as number of sexual partners, ever having an abnormal Pap smear, sexually 
transmitted disease, smoking and parity.   
 The results of the study suggest significance (p<0.001) in the prevalence of HPV in cases 
with high-grade VIN (48 of 54 or 88.9%), basaloid-warty carcinoma (BWC) (18 of 21 or 85.6%) and 
keratinizing squamous carcinoma (KSC) (3 of 48 or 6.3%) compared to controls.  However, when 
risk factors for BWC were compared to KSC, BWC was significantly associated with cervical 
cancer risk factors such as number of sexual partners, age at first intercourse, abnormal Pap smears, 
venereal warts, low socioeconomic status and smoking, while KSC was less strongly linked to these 
factors (Trimble, et al. 1996).  Furthermore, KSC was found primarily in older women (mean age 
65.1 years) and was less related to being HPV DNA positive (6.3%), which suggests that there are 
two etiologies of vulvar cancer. This finding is of particular interest to the present study (Table 3) in 
supporting the suggestion that vulvar cancer in older women is less related to HPV DNA than vulvar 
cancer in younger women. 
 The limitations to the Trimble, et al. (1996) study include the small study size.  Another 
limitation, with respect to the present one, is that the questionnaire asked respondents if they ever 
had an abnormal Pap smear, but did not provide information regarding if respondents had ever had a 
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Pap smear.  It is conceivable that respondents may not have ever had an abnormal Pap smear simply 
because they never had a Pap smear. 
Sera were collected in Heim, et al. (2005)’s study to perform various tests for the detection of 
specific HPV antibodies in subjects with vulvar precancerous and invasive lesions. The Heim, et al. 
(2005) study was conducted to suggest the best HPV serology test for the detection of specific 
antibodies in patients with vulvar cancer.  The study also sought to determine whether populations 
exposed to specific HPV types are at greater risk of precancerous and invasive lesions of the vulva 
(i.e., vulvar lichen sclerosus (LS), VIN1, VIN2, VIN3, verrucous carcinoma (VC) and giant 
condyloma Buschke Lowenstein tumor).  The study utilized 97 cases diagnosed with lichen 
sclerosus with and without squamous hyperplasia, 78 cases diagnosed with VIN and 16 cases with 
verrucous carcinoma and 126 healthy controls ranging in age from 16 to 81 years.   
The results of the study indicate that in lichen sclerosus/squamous hyperplasia with atypia 
immunoglobulins G and A, antibody positivity rates to high-risk HPV types 16, 18 and 31 were 
significantly higher in cases than in the control group and the lichen sclerosus/squamous hyperplasia 
group without atypia.  In cases with VIN1, increased immunoglobulin G antibody prevalence with 
both high-risk and low-risk (types 6 and 11) HPV particles were detected.  In cases with VIN2 and 
VIN3, increased immunoglobulin G was detected with only HPV high-risk types. 
The study suggests that high-risk HPV types, such as HPV16 play a role in the pathogenesis 
of precancerous and invasive vulvar lesions.  However, the conclusions of this study should be 
perceived with caution.  First, all subjects were Caucasian.  Second, controls were chosen from 
women who visited the outpatient clinic for treatment for non-HPV related diseases.  Third, the 
population sample used for the study was small and segmented into numerous types of vulvar 
anomalies (97 with lichen sclerosus with and without squamous hyperplasia, 78 with VIN and 16 
with verrucous carcinoma) making it difficult to suggest with any certainty where HPV plays a role 
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in the development of precancerous and invasive lesions among older women.  Analysis of age strata 
and how the sera were collected might have been useful.  Furthermore, the study was not population 
based, which reduces the ability to generalize to a larger, more diverse population. 
 Hildesheim, et al. (1997a)’s study also collected sera to determine association with HPV 
types and risk of VIN3 and invasive vulvar cancer. The purpose of the study was to investigate 
whether a causal relationship between HPV16 and other risk factors were related to vulvar 
carcinoma, including contraceptive use, reproductive history, cigarette smoking and sexual behavior.  
The study included 142 cases histologically confirmed with VIN3 or invasive vulvar cancer and 126 
controls matched on age, race and residence.  The cases and controls ranged in age from 20 to 79 
years.   
The results of the study suggest that cases that tested positive for HPV16 had an adjusted 5.3 
fold excess risk of vulvar cancer (adjusted OR 5.3, 95% CI 2.5-11.1).  Subjects with high antibody 
levels have a 20 fold risk of vulvar cancer relative to those who tested negative (adjusted OR 20.1, 
95% CI 5.4-76.7).  Furthermore, a strong association was observed between HPV16 positivity and 
VIN3 (adjusted OR 13.4, 95% CI 3.9-46.5).  A two-fold risk for HPV 16 positivity was observed 
among subjects with invasive vulvar cancer (adjusted OR 2.9, 95% CI 0.94-8.7).    
The study also suggested other significant risk factors such as greater than two sexual 
partners (adjusted OR 2.8 and adjusted OR 2.4, 95% CI 0.93-6.0); greater than three sexual partners 
(adjusted OR 4.7 and adjusted OR 3.4, 95% CI 1.5-7.7); herpes simplex virus (HSV 1) (adjusted OR 
2.7 and adjusted OR 2.5, 95% CI 1.1-6.0); and HSV2 (adjusted OR 3.6 and adjusted OR 3.2, 95% CI 
1.0-10).  For cases who tested HPV16 positive the risk of vulvar cancer was more than twice that 
observed among smokers than those who never smoked (OR 8.5 and 3.4); greater risk was observed 
among women who tested positive for c. trachomatis than those who tested negative (OR 7.6 and 
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6.2), and slightly greater risk among those who used oral contraceptives than those who never used 
them (OR 8.3 and OR 7.2).   
The small study size did not allow the researchers to report on age strata which would have 
been of interest to this study.  Furthermore, the study did not collect information regarding pelvic 
examination and Pap smear screening histories. 
The study by Mabuchi, et al. (1985) utilized a matched case-control design that used hospital 
data and interviews that collected gynecologic history, but did not include Pap smear or pelvic 
examination histories to estimate the risk of vulvar cancer.  The study included 149 cases 
histologically confirmed vulvar carcinoma and 149 controls that are matched on race, age, marital 
status and geographic area.  Participants ranged in age from 30 to over 80 years old.   
 Cases and controls were interviewed to obtain demographic information, occupation, 
hazardous exposures (e.g., metals, dyes, radioactive materials, chemicals, sawdust, cement dust, coal 
and/or other dust, paints, dry cleaning/dying materials, gasoline/grease, textile machinery and cutlery 
machinery), habits, marital status, coital status, reproductive and menstrual history, medications, 
cigarette smoking status, coffee drinking status, religious affiliation, education and medical history.  
For each case interviewed, a control was matched based on the results of the interviews to determine 
hospital, sex, race, age (plus or minus 3 years) and marital status.  The interviewers were blinded to 
the case/control status of the participants interviewed. 
 The statistically significant results suggested by Mabuchi, et al. (1985), include associations 
with employment as private household maids and servants (24 cases/12 controls, OR 2.19, p<0.05); 
in laundry, cleaning and other garment services (13 cases/3 controls, OR 3.81, p<0.05); and age 
(average 30) at first marriage (27 cases/17 controls, OR 3.29, p<0.05); cigarette smoking of 10 to 20 
cigarettes per day (28 cases/13 controls, OR 2.46, p<0.05); coffee consumption of 3-4 cups (44 
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cases/28 controls, OR 2.99, p<0.05); coffee consumption of 5 or more cups per day (42 cases/33 
controls, OR 2.42, p<0.05).   
 The study also found that a history of leukoplakia (13 cases/0 controls, p<0.005) and 
inflammation of the vulva or vagina (17 cases/2 controls, p<0.005) was reported (Mabuchi, et al. 
1985).  The frequency of prior cervical cancer was borderline significant (p<0.10) (five (5) of the six 
(6) cases who reported prior cancer had cervical cancer between 6 and 20 years before vulvar 
cancer).  
 The limitations of the study include a small sample size.  Furthermore, the majority of both 
cases and controls were white (90%) and between the ages of 50 and 79 years (72%) with similar 
socioeconomic backgrounds.  In addition, the controls were hospital controls making it difficult to 
generalize to the population.  However, for the benefit of the present study (Osterbur’s), the majority 
of patients with vulvar carcinoma were between the ages of 50 and 79 years which shows that vulvar 
carcinoma occurs more frequently among this age group.  Age stratification for type and risk factors 
associated with vulvar cancer would have been useful, but because of the sample size this was not 
possible.  Furthermore, while information was collected via interview for both cases and controls 
regarding various health prevention measures, history of pelvic examinations and Pap smears was 
not reported.   
Summary of case-control studies 
 The primary purpose of the above case-control studies was to determine the etiology of 
vulvar cancer.  Basta, et al. (1999) obtained both Pap smears and colposcopies to determine the role 
of HPV in the development of VIN1 and early stage vulvar cancer; while Trimble, et al. (1996) 
collected information on abnormal Pap smear histories.  Both studies suggest that the role of HPV is 
a significant risk factor among younger women and a non-significant risk in older women, in 
accordance with other literature.  These case-control studies also collected Pap smear histories and 
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found that women with no previous Pap smears were at greater risk than those who did have a 
previous Pap smear (Brinton, et al. 1990a, Parazzini, et al. 1993).   
The Madeleine, et al. (1997), Sherman, et al. (1994), Heim, et al. (2005), Hildesheim, et al. 
(1997a), and Mabuchi, et al. (1985), studies did not collect information on previous pelvic 
examinations or Pap smear histories.  However, the Madeleine, et al. (1997) and Mabuchi, et al. 
(1985) studies suggest that vulvar carcinoma is more common among older women.  Madeleine, et 
al. (1997) found over half of cases that had invasive disease were over age 60 and Mabuchi, et al. 
(1985) between the ages of 50 and 79.  Hildesheim, et al. (1997a) suggested that HPV was a risk 
factor in the development of invasive vulvar cancer.   
While several studies took into account both pelvic examinations and Pap smears, they did 
not take into account specifically the potential lower use associated with gynecological screening.  
The present study serves to fill this gap in the literature.  The following Table 4 summarizes the 
above-mentioned case-control studies.
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Table 4. Vulvar cancer: case-control studies 
 
 Diagnosis year Study Cases Controls Purpose Age 
Basta, Adamed and Pitynski (1999) 1982-1996 Case-control 178 115 Risk factors  
       
Brinton, Nasca, Mallin, Baptiste, 
Wilbanks and Richart (1980) 
1986 Matched case-control 
 
209 348 Risk factors 20-79 
       
Heim, Widschwendter, Szedenik, 
Greir, Christensen, Bergant, Concin 
and Hopfl (2005) 
1991-1994 Case-control 
Group 1 
Group 2 
Group 3 
Group 4 
Group 5 
 
 
97 (LS w/wo SH) 
17 (VIN 1) 
61 (VIN 1 or 111) 
Serologic response  
to HPV 
 
     28-80 
     19-37 
     18-77 
 
  16 (VC of the vulva) 
126 (chosen randomly for TX of non-HPV) 
           39-79  
             16-81 
   
Hildesheim, Han, Brinton, Kurman 
and Schiller (1997) 
1985-1987 Case-control 142 126 HPV 20-79 
       
Mabuchi, Bross and Kessler (1985) 1972-1975 Matched case-control 149 149 Risk factors 30-80 
       
Madeleine, Daling, Carter, Wipf, 
Schwartz, McKnight, Kurman, 
Beckmann, Hagensee, Galloway 
(1997) 
1980-1994 Matched case-control 510 1,403 Cofactors with 
HPV 
19-79 
       
Parazzini, La Vecchi, Garsia, Negri, 
Sideri, Rognoni and Origoni (1993) 
1987-1990 Case-control 73 572 Risk factors 38-74 
       
Sherman, Daling, McKnight and Chu 
(1994) 
1980-1990 Case-control 330 1,010 Hormonal 
factors 
18-79 
       
Trimble, Hildesheim, Brinton, Shah 
and Kurman (1996) 
One year 
retrospective 
and 18 months 
prospective 
Case-control 123 246 Role of HPV 20-70 
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Prior research of vaginal and vulvar cancers 
Case-control study 
The Jamieson, et al. (2006)’s study performed both Pap smears and physical (pelvic) 
examinations to determine HPV status, as well as colposcopy to determine precancer status and 
human immunodeficiency virus (HIV) screening (cluster of differentiation (CD) 4 counts)) to test 
their hypotheses that HIV is a risk factor in the etiology of vulvar, vaginal and perianal 
intraepithelial neoplasia.  It should be noted the study, while collecting data relative to HPV and 
HIV, also collected (via interview) data relative to risk factors such as sexual behaviors and injection 
drug use among women between the ages of 16 and 55.  Antiretroviral therapy use was also accessed 
via self-report by HIV infected cases.   
The study included 189 cases that were HIV-infected women and 88 controls who were at 
high-risk for HIV.  Two participants (who were not diagnosed with vulvar, vaginal or anal 
intraepithelial neoplasia) in the study seroconverted -- status changed from HIV negative to HIV 
positive -- and were included in the study until the event of seroconversion.  There were 16 HIV-
infected cases with vulvar, vaginal or anal intraepithelial neoplasia and only one had a normal Pap 
smear.  Conversely, only one of the HIV-uninfected controls, while having a normal Pap smear, also 
had VIN (visible lesions were noted on physical examination).   Furthermore, 10 cases diagnosed 
with vulvar, vaginal or anal intraepithelial neoplasia were also diagnosed with cervical intraepithelial 
neoplasia (CIN). 
The study suggests that significant risk factors for development of vulvar, vaginal and 
perianal intraepithelial neoplasia among HIV-infected cases include CD4 counts (cells/µL) less than 
200 (unadjusted Hazard Ratio (HR) 6.6, 95% CI 1.2-36.4); CD4 counts (cells/µL) between 200 and 
500 (unadjusted HR 3.5, 95% CI 0.8-15.8); HPV PCR positive, any type (unadjusted HR 5.0, 95% 
CI 1.1-22.0); HPV PCR positive, high/intermediate risk type (unadjusted HR 3.1, 95% CI 1.1-8.8); 
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cervical, vaginal or vulvar condyloma noted at baseline physical exam (unadjusted HR 2.0, 95% CI 
0.7-6.2) and antiretroviral use at baseline (unadjusted HR 3.9, 95% CI 1.3-11.1).   
Summary of case-control study 
 Jamieson, et al. (2006) suggested that HIV-infected women have a higher risk of lower 
genital tract intraepithelial neoplasia that is not limited to the cervix and recommended that the 
vulvar, vaginal and perianal regions be inspected during gynecologic exams.  This study utilized 
both Pap smears and pelvic examinations; however, the study focus was on younger women (16-55 
years) who tested positive for HIV.   
Screening 
Definition and rationale for screening 
 According to Sankankaranayanan, et al. (2005), the purpose of population screening policies 
is to divide the population into two groups: those with a low risk of disease and those with a high 
risk of disease who may warrant further diagnostic testing or examinations.  Screening is applied to 
people who are asymptomatic and who meet the eligibility requirements for the screen.  The purpose 
is to identify individuals whose disease is pre-invasive so that it can be effectively treated before 
becoming invasive.  The disease screened must have a detectable preclinical stage for which 
effective treatment is available.  The justification for any screening program is that early diagnosis 
will lead to a cost-effective and measurable reduction in invasive or late stage cancer.  
 Weiss (1999) suggested there is a natural history of cancer development wherein, during the 
pre-invasive detectable phase (PIDP) "changes occur in a particular tissue that pre-dispose to the 
development of cancer."  It is during this time frame when screening tests are effective for 
determining precursor cancer lesions (i.e., vulvar intraepithelial neoplasia or vaginal intraepithelial 
neoplasia) (Figure 1).  These changes may be present for a specific time period (i.e., years in the case 
of vaginal and vulvar cancers).  The following Figure 1 illustrates this concept.  
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Age 
 
Birth      PIDP    OIP    Death 
 
 
 
  
      Progression 
    
     Regression 
 Oncogenic       Invasion        Invasive 
   Changes                Cancer is 
     Begin               Diagnosable 
  
Adapted from David Maduram MD/PhD, University of Illinois,  
“An analysis of the efficacy of cervical cancer screening in elderly women”, 2009 
Figure 1: Pre-invasive detectable phase (PIDP) and occult invasive phase (OIP) 
Current policy recommendations for screening 
Policy recommendations such as when to start and stop screening and screening frequency 
intervals for cervical lesions differ across professional and governmental organizations.  The 
intervals for performing pelvic examinations and Pap smears in older women have been strongly 
debated among researchers and policymakers. The following Table 5 illustrates these differences.
VIN/VAIN 1 
Mild 
Dysplasia 
VIN/VAIN 2 
Moderate 
Dylplasia 
VIN/VAIN 3 
Severe 
Dysplasia 
VIS/VAIS 
“In Situ” 
FIGO I-IV 
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Table 5. Cervical cancer screening guidelines, 1988, 1996, 2002, 2003, 2012 
 
 
 
 
 
 
 
 
 
 
1988 
Consensus 
 
1996 
American 
Academy of 
Family 
Physicians 
(AAFP) 
 
 
 
 
2002 
American Cancer 
Society (ACS) 
 
2003 
American 
Congress of 
Obstetrics and 
Gynecology 
(ACOG) 
 
2003 
United States 
Preventive 
Services Task 
Force 
(USPSTF) 
 
 
 
 
 
2012 
USPSTF 
       
When to start 
screening 
Age 18 or with onset 
of sexual intercourse 
Every 3 years after 
onset of sexual 
intercourse and have a 
cervix 
Age 21 or about 3 years 
after onset of sexual 
intercourse 
Age 21 or about 3 years 
after onset of sexual 
intercourse 
Age 21 or about 3 
years after onset of 
vaginal intercourse 
Age 21, recommends 
against screening with 
HPV testing, alone or 
in combination with 
cytology in women 
younger than 30 
       
Screening 
interval 
Annually until 3 
consecutive, 
satisfactory negatives, 
then interval may be 
extended at discretion 
of provider 
Every 3 years Annually until age 30. 
Every 2 years if liquid-
based cytology or age 
30 or older after 3 
consecutive satisfactory 
negatives may screen 
every 2-3 years 
Annually until age 30 
using either conventional 
or liquid-based cytology 
or age 30 or older after 3 
consecutive satisfactory 
negatives and no history 
of CIN2 or 3, may screen 
every 3 years 
Every 3 years Every 3 years with 
cytology, or women 
age 30-65 who want to 
lengthen screening 
interval, screening 
with combination of 
cytology and HPV 
testing every 5 years 
       
When to stop 
screening 
No upper limit No recommendation Age 70 in well-
screened, low-risk 
women 
Evidence inclusive to set 
upper age 
Age 65 in well-
screened low-risk 
women 
Age 65 in well-
screened low-risk 
women who are not 
otherwise at high-risk 
for cervical cancer 
       
Posthysterectomy No recommendation Discontinue after 
hysterectomy if cervix 
removed 
Discontinue after 
hysterectomy for benign 
disease if cervix 
removed, if no prior 
CIN2 or 3 
Discontinue after 
hysterectomy for benign 
disease if cervix 
removed, if no prior 
CIN2 or 3 
Discontinue after 
hysterectomy if no 
evidence of cervical 
neoplasia or cancer 
Discontinue after 
hysterectomy with 
removal of cervix, if 
no prior CIN2 or 3 
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The 1988 consensus statement (Table 5) recommended that starting at age 18 or with the 
onset of sexual activity, all women should have an annual pelvic examination, including a Pap 
test (Waxman, 2005).  The 1988 consensus statement was upheld by professional and 
governmental organizations and supported by practitioners until 1995, when the American 
Congress of Obstetrics and Gynecology (ACOG) issued a committee opinion that listed risk-
based exceptions to the extended screening interval including a list of social and demographic 
risk factors, as well as items related to risk including sexually transmitted diseases, multiple 
partners and low socio-economic status (SES).  Since then, medical research and technology 
have increased our understanding of the pathogenesis of cervical cancer and the role of HPV in 
the development of cervical and vaginal cancers.  Furthermore, since new screening methods are 
available to practitioners, more studies that deal with screening efficacy and cost-effectiveness 
have all led to differences in screening recommendations among professional and governmental 
organizations. 
In 2001, the American Geriatrics Society issued a position statement on the screening for 
cervical carcinoma in older women (AGS, 2001).  It suggests that the recommendations by such 
professional organizations as the ACS and ACOG do not take into account the risk factors for the 
development of cervical carcinoma in older women.  Taking account of risk factors such as 
multiple sex partners, history of HPV, HIV, cervical dysplasia, smoking and immunosuppression 
may suggest that the frequency of cervical cancer may increase in older women.  Further, the 
AGS guidelines suggest that the present recommendations assume that women younger than 60 
have frequent screenings when studies reveal that between 28% and 64% of women age 65 and 
older have never had a Pap smear or have not had one performed within the past within three 
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years.  The AGS suggests that this may account for the high rate of invasive disease in older 
women.       
The National Cancer Institute at the National Institutes of Health (NIH) Cervical Cancer 
Screening PDQ® last updated in 2012, suggests that cervical cancer mortality increases with age, 
especially among women who have never been screened.  These unscreened populations include 
older women, a higher population of the uninsured, ethnic minorities, especially elderly Hispanic 
and black women and poor women, particularly those who live in rural areas.   
Conversely, there are authors who suggest that cervical cancer screening should stop at 
age 50 for women who have had regular Pap tests prior to age 50 with negative results 
(Cruickshank, et al. 1997).  Similarly, other authors suggest that stopping Pap smears at age 50 
may be more appropriate provided that such women had at least three consecutive Pap smears 
with negative results (Van Wijngaarden and Duncan, 1993, Flannelly, et al. 2004).  Flannelly, et 
al. (2004) further suggested that women with a positive Pap smear result history should continue 
screening after 50 years of age.    
The U.S. Preventive Service Task Force (USPSTF) has suggested that routine Pap smears 
are unnecessary for women who have had a hysterectomy with removal of the cervix for benign 
disease (Sirovich and Welch, 2004b).  Furthermore, Fetters, et al. (2003) suggests that vaginal 
Pap smears in women with a prior hysterectomy for benign disease is not worthwhile.   
Medicare screening policies 
 The USPSTF was formed in 1984 to address the inconsistencies among clinicians 
regarding the effectiveness of preventive interventions (Richardson, 2006).  The USPSTF 
consists of experts from various fields to evaluate the effectiveness of these interventions.  
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Medicare coverage for preventive services adheres closely to the recommendations of the 
USPSTF. 
 Prior to July 1990, Medicare coverage for Pap smears was extended only to beneficiaries 
who were being treated for an existing gynecological cancer or for those at risk for disease, but 
did not cover routine screening (CMS, 1990).  After July 1990, Medicare coverage for Pap smear 
screening was extended to beneficiaries of Medicare Part B after a study conducted by the 
congressional Office of Technology Assessment (OTA begun in 1972 and defunded in 1995) 
found that about 25% of new cases of invasive cervical cancer occur in women age 65 and older.  
The OTA also suggested that about half of older women have had a Pap smear within the past 
three years and one out of every four women have never had a Pap smear.  The OTA estimated 
that screening older women would save approximately 21,400 life years per one million women 
screened.   
 To encourage screening in older women, Medicare provides funding for gynecological 
screenings.  As such, from July 1990 until July 2001, Pap smears were reimbursed by Medicare 
every three years for low-risk women and every two years for high-risk women (CMS, 2004).   
This policy covers my study observation period, which includes the years from 1991 to 1999.  
(However this policy, updated in July 2001, currently reimburses screening Pap smears every 
two (2) years for low-risk women (CMS, 2004).  This policy update does not affect my study 
population.)  Furthermore, since January 1998, pelvic examination and Pap smear screenings 
were reimbursed annually for high-risk women.  Medicare coverage of pelvic examinations 
without Pap smears was recommended to all female beneficiaries as of January 1998, affecting 
only two (2) years of this study population (the years 1998 and 1999).    
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The following Tables 6 and 7 illustrate Medicare Part B coverage for both pelvic 
examinations and Pap smears   
Table 6. Medicare Part B coverage 2005-2010 
 
 
  
Service What Medicare covers What beneficiaries pay 
Pap test One Pap test every 24 months, 
unless in high risk group, 
Medicare will pay for a Pap 
test once every 12 months 
20% of the Medicare approved 
amount for the part of the 
exam when the doctor/health 
care provider collects the 
specimen.  Beneficiaries pay 
nothing for lab Pap test.  No 
Part B deductible for this 
service 
   
Pelvic examination/clinical 
breast examination 
One pelvic/clinical breast 
examination every 24 months, 
unless in high risk group, 
Medicare will help pay for a 
pelvic examination once every 
12 months 
20% of the Medicare-
approved amount.  No Part B 
deductible for this service 
Adapted from Women with Medicare: Visiting your doctor for a Pap test, pelvic exam, and clinical breast exam, U.S. Department 
of Health and Human Services (DHHS), Centers for Medicare and Medicaid Services (CMS). Rev. July 2005. 
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Table 7. Pelvic examination procedures according to Medicare Part B 1990-2010 
  
 Payment for screening pelvic examinations performed on asymptomatic women occurred 
only if a previous screening had not been performed or paid for by Medicare within three years 
in which the last Medicare-covered screening was performed (CMS, 2006). 
 The Patient Protection and Affordable Care Act (May 2010), makes it possible for 
beneficiaries of original Medicare to qualify for a yearly wellness visit and many preventive 
services for free.  As of January 1, 2011, cervical cancer screening, including Pap smear and 
pelvic examination is available without the need for Medicare Part B deductible or copayment 
(DHHS, 2012). 
Definition and mechanisms of screening pelvic examination and Pap smears (gynecologic)  
 A Pap smear is a microscopic examination of cells scraped from the cervix.  Vaginal 
cancer can be detected by routine Pap smear and pelvic examination in 20% of cases (Averette, 
Years Pelvic examination procedures 
1990-1997 Preventive services for cervical or vaginal screening were not covered by Medicare during these 
years unless treated for pre-existing condition 
1998-2010 Screening pelvic examination (of the following procedures at least 7 must be performed) 
 Inspection and palpation of breasts for masses or lumps, tenderness, symmetry or 
nipple discharge 
 Digital rectal examination including sphincter tone, presence of hemorrhoids and rectal 
masses 
 Pelvic examination, with or without specimen collection for smears and cultures, 
including: 
o Inspection of external genitalia for general appearance, hair distribution or 
lesions 
o Inspection of urethral meatus for size, location, lesions or prolapse 
o Inspection of the bladder for fullness, masses or tenderness 
o Inspection of the vagina for general appearance, estrogen effect, discharge, 
lesions, pelvis support, cystocele or rectocele 
o Inspection of the cervix for general appearance, lesions or discharge 
o Inspection of the uterus for size, contour, position, mobility, tenderness, 
consistency, descent, or support 
o Inspection of the adnexa/parametria for masses, tenderness, organomegaly or 
nodularity 
o Inspection of the anus and perineum 
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et al. 1993).  However, vaginal cancer often presents symptoms such as postmenopausal 
spotting, bleeding, foul discharge and pain.  After an abnormal Pap smear or presentation of 
symptoms, a colposcopic investigation is required of the vaginal walls.   
 Vulvar cancer too, can be detected via routine Pap smear and pelvic examination, but the 
majority of patients present with symptoms such as a long history of itching or burning (Kagie 
and Ansink, 2000, Canavan and Cohen, 2002, Averette, et al. 1993).  Since the vulva is an 
external organ, early detection can be readily achieved via routine pelvic examination (Averette, 
et al. 1993).   
 For purposes of this study, while there are other screening methods, the study analyzes 
the efficacy of pelvic examinations performed at the time of Pap smear alone.  Following are 
terminology to describe pelvic examination and Pap smear cytology. 
 Pap smear cytology 
The conventional Pap smear, developed by Dr. George N. Papanicolaou, has been used in 
screening for cervical cancer since its inception in 1950. Exfoliated cells in body tissues and 
fluid are examined to determine the specific types of cells present (Fischbach, 2004).  
Gynecologic specimens are smeared and fixed in 95% alcohol.  A spray fixative is also used 
to preserve the sample.  All specimens are examined for the number of cells, cell 
distribution, surface modification, size, shape, appearance and staining properties.  The cell 
nucleus is also examined.  Abnormal cells can be identified to determine malignant and 
premalignant conditions.  This method did not change until 1988 with the implementation of 
the Bethesda System that allows for the standardization of cervical cytology and reporting 
terminology.  Plus, new advances in smear technology such as the ThinPrep, a liquid-based 
technique that collects smears in a special preservative solution (Fischbach, 2004) allows for 
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more accurate interpretations of cancer (cervical, vaginal and vulvar) precursors.  A more 
recent advancement in gynecological cancer screening is HPV co-testing that serves to 
detect high-risk HPV types. In practice, results of cytologic studies are commonly reported 
as: 
o Inflammatory 
o Benign 
o Atypical 
o Suspicious for malignancy 
o Positive for malignancy (invasive versus in situ) 
 Pelvic examination 
A pelvic examination is a physical examination of the uterus, vagina, vulva, ovaries, 
fallopian tubes, bladder and rectum (Bates, et al. 2011).  The vulva and introitus (opening of 
the vagina) are inspected for hair pattern over lower abdomen, groin and mons publis.  The 
skin is inspected for changes, concerning nevi (moles) and lesions and the labia major and 
minora are also inspected along with the size of the clitoris, urethra, introitus and hymen.  
Careful inspection is important for lesions of the vulva and is the most productive diagnostic 
technique.  It utilizes a speculum to examine the cervix and vagina for any anomalies. 
Screening and diagnosis of vaginal cancer 
 
In the beginning phase of disease, generally there are no symptoms (Greene, et al. 2002, 
Creasman, 2005, Bardawil, 2010).  However, once invasive vaginal cancer reaches advanced 
stages symptoms begin to manifest themselves.  Many symptoms may be similar to other 
medical conditions experienced by older women (Greene, et al. 2002).    
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The most common symptom of vaginal cancer is abnormal vaginal bleeding (Greene, et 
al. 2002, Stern, 2002, Creasman, 2005, Tewari, et al. 2001, Bardawil, 2010) and even during 
menopause abnormal vaginal bleeding is a sign of a problem (Greene, et al. 2002).  Other 
symptoms include abnormal vaginal discharge, difficulty or pain when urinating, pain during 
sexual intercourse, pelvic pain (lower part of the abdomen between the hip bones), pain in the 
back of the legs and edema (Greene, et al. 2002, Stern, 2002, Bardawil, 2010). 
 When a diagnosis is made, several factors such as age and medical condition of the 
patient, the type of cancer, severity of symptoms and any previous test results are considered for 
follow-up and treatment.  The following Table 8 illustrates the various types of diagnostic and 
screening tools that are useful in screening and diagnosing vaginal cancer (The College Faculty 
of the University of Washington, 2005). 
Table 8. Diagnostic tools to screen and diagnose vaginal cancer 
Test Vaginal 
Pelvic examination Yes 
Pap smear Yes 
Colposcopy Yes 
Biopsy Yes 
X-ray Yes 
CT/CAT scan Yes 
MRI/PET scan No 
Cystoscopy Yes 
Proctoscopy Yes 
Pelvic examination (anesthesia) Yes 
   
  
Tewari, et al. (2001) studied 71 patients with primary vaginal carcinoma.   Half of the 
study population presented with vaginal bleeding, 26% presented with vaginal pain or 
dysparunia and 20% with asymptomatic who were diagnosed via vaginal biopsy of a lesion 
found during a routine pelvic examination.  Similarly, Bardawil (2010) recommends that during 
a routine pelvic examination there should be not only visual examination of the vagina, but also 
51 
 
the palpation of the entire vagina in order to feel any hardened or raised areas that may indicate a 
residual tumor.  A routine Pap smear may indicate an abnormality in a patient with carcinoma in 
situ or in a patient with very early invasive disease who is asymptomatic.  Further, VAIN tends 
to be multi-focal and, as such, if a lesion is identified the entire vagina needs to be inspected for 
multiple lesions (Sillman, 2000).    
Sillman (2000), however, suggested that in about 90% of cases, an abnormal Pap smear 
(cervical or vaginal) precedes diagnosis.  Sillman (2000) suggested that the remaining 10% of 
cases are found through colposcopic survey of high-risk patients (such as those with HPV, other 
anogenital neoplasm or immunosuppression) or in women who have been exposed to DES 
(Stern, 2002).    
ACS (2012d) has suggested that both a routine pelvic examination and Pap test, where a 
sample of cervical or vaginal cells is collected for laboratory analysis, are necessary for a 
diagnosis of vaginal cancer.  A colposcope may be used to view the vagina.  If any abnormalities 
are detected, a tissue biopsy may also be taken to aid in the diagnosis.  If metastases are 
suspected, an endoscopic examination of the bladder (cystoscopy) and/or rectum (proctoscopy) 
may also be performed.  
Staging vaginal cancer  
Staging, according to the International Federation of Gynecology and Obstetrics (FIGO), 
is clinical and not surgical (Stehman, 1997).  Staging is utilized to describe where the cancer is 
located, if and to where it has spread and if the cancer is invading other organs in the body 
(FIGO, 2000).  Staging is useful for identifying prognosis and determining the choice of 
treatment (FIGO, 2000).  Different cancers typically have their own staging criteria (FIGO, 
2000).   
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Table 9 provides the explanation of the FIGO staging of invasive cancer of the vagina.  
TNM is the abbreviation for tumor (T) which indicates how large and where the primary tumor is 
located; node (N) indicates if the tumor has spread to adjacent lymph nodes, and metastasis (M) 
indicates if the cancer has metastasized to other parts of the body  (AJCC, 2002).   
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Table 9. FIGO staging of invasive cancer of the vagina 
______________________________________________________________________ 
Stage 0 
Tis N0 M0 Carcinoma in situ, intraepithelial carcinoma 
 
Stage I 
T1 N0 M0 Carcinoma is limited to the vaginal wall 
    
Stage II 
T2 N0 M0 Carcinoma has involved the subvaginal tissue but has not 
   extended to the pelvic wall 
 
Stage III  Carcinoma has extended to the pelvic wall 
T1 N1 M0 
T2 N1 M0  
T3 N0 M0  
T3 N1 M0  
 
Stage IV  Carcinoma has extended beyond the true pelvis or has involved 
   the mucosa of the bladder or rectum; bullous edema as such  
   does not permit a case to be allotted to Stage IV 
  
Stage IVa  Spread of the growth to the adjacent organs and/or direct 
   extension beyond the true pelvis. 
T1 N2 M0  
T2 N2 M0 
T3 N2 M0 
T4 Any N M0 
 
Stage IVb   Spread to distant organs 
Any T Any N M1  
______________________________________________________________________________ 
Adapted from Stehman, 1997, p. 599. 
 
 The five-year survival rates of vaginal cancer vary according to the various stages of 
disease.  Table 10 of squamous cell carcinoma of the vagina survival rates by stage and age 
illustrates the premise that as stage of disease increases, five-year survival rate decreases.   
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Table 10: Squamous cell carcinoma of the vagina:  
survival rates by stage and age 1988-2001* 
 Relative 5-Year Survival Rate (%) 
Stage 20-60 70+ 
I 72.9 61.9 
II 61.7 43.3 
III 33.0 37.0 
IV 23.6 17.4 
*AJCC (SEER modified, 3
rd
 edition) 
 
Screening and diagnosis of vulvar cancer 
Vulvar cancer has different symptoms than vaginal carcinoma.  The most common is 
pruritus (severe chronic itching) (Kagie and Ansink, 2000, Canavan and Cohen, 2002).  Burning 
pain of the vulvar area, dysparunia (painful sexual intercourse), changes in the color of the vulva, 
bleeding or discharge not related to menstruation or the vulvar skin that appears white and feels 
rough are symptoms of vulvar cancer (Kagie and Ansink, 2000, Jones and Rowland, 2009).  
Similar to vaginal cancer, vulvar cancer symptoms often resemble other conditions or medical 
problems (Greene, et al. 2002).   
Vulvar cancer is a disease which is characterized by delayed diagnosis where diagnosis, 
even when symptoms such as pruritus and irritation are present.  Symptoms are often ignored by 
both patients and practitioners based on their non-specific nature (ACS, 2012a). 
When VIN is diagnosed histologically, the vagina and the cervix should be fully 
examined as well to determine if there are any co-morbid conditions since there is a high 
incidence of the concurrence of vaginal and cervical cancers (Kagie and Ansink, 2000).  The 
following Table 11 illustrates the various types of screening and diagnostic tools to identify 
vulvar cancer. 
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Table 11. Diagnostic tools to screen and diagnose vulvar cancer 
Test Vulvar 
Pelvic examination Yes 
Pap smear Yes 
Colposcopy Yes 
Biopsy Yes 
X-ray Yes 
CT/CAT scan Yes 
MRI/PET scan Yes 
Cystoscopy Yes 
Proctoscopy Yes 
Pelvic examination (anesthesia) Yes 
 
 This is no specific screening procedure for vulvar cancer (Homesley, 1995, Stehman, 
1997).  According to Stehman (1997), careful visual inspection of the vulva during routine 
physical examination is the most useful technique in diagnosis.  Furthermore, a history of prior 
Pap smears has been associated with a decreased risk of vulvar cancer (Sturgeon and Sherman, 
2000).  Sturgeon and Sherman (2000) further suggested that patients who participate in Pap 
smear programs are more likely to also undergo a routine pelvic examination which allows for 
early detection and treatment of vulvar cancer.   
 However, patients who have had a history of cervical or vaginal cancer should have the 
vulva inspected with or without coloposcopic examination (Benedet, et al. 2000).  Colposcopic 
examination is more reliable for ruling out vaginal or cervical cancer than it is for ruling out 
invasive carcinoma of the vulva; patients should undergo colposcopy of the cervix, vagina and 
vulva before treatment is prescribed (Homesley, 1995).   
Both colposcopic examination and biopsies are essential in diagnosing vulvar lesions 
(Kagie and Ansink, 2000).  However, the value of a detailed vulvoscopy is debatable based on 
the keratinized, squamous, hair bearing tissues of the vulva (Sideri, et al. 2009) where lesions 
occur.   Multiple biopsies may be necessary in the evaluation of suspicious lesions (Homesley, 
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1995, Stehman, 1997).  A punch biopsy, best accomplished under local anesthesia, should be 
performed because it provides full-thickness skin specimens (Stehman, 1997, Kagie and Ansink, 
2000, Sideri, et al. 2009).    
While palpation of the groin is part of the assessment of vulvar carcinoma it is not 
reliable -- creating false-negative rates of 23% and false-positive rates of 60% (Sideri, et al. 
2009).  Furthermore, radiology, including computed tomography (CT) and magnetic resonance 
imaging (MRI) are also not reliable instruments for the diagnosis of vulvar carcinoma.   
 The initial diagnosis should be established based on histology, because other methods, 
such as gross appearance or cytology, are unreliable (Kagie and Ansink, 2000).  Because of the 
high incidence of the coexistence of VAIN and/or CIN, the vagina and cervix should both be 
fully assessed.   
Staging vulvar cancer  
 Table 12 below illustrates the five-year survival rates for squamous cell carcinoma of the 
vulva.  The later the stage of disease and the older the age, the relative five-year survival rate 
decreases.  However, at early stages of disease, there are higher rates of survival. 
Table 12: Squamous cell carcinoma of the vulva,  
by stage and age 1988-2001* 
 Relative 5-Year Survival Rate (%) 
Stage 20-60 70+ 
I 94.0 92.9 
II 86.0 73.1 
III 70.0 39.7 
IV 40.6 16.9 
*AJCC (SEER modified, 5
th
 edition) 
  
 The staging for vulvar cancer is also staged according to the FIGO.   The following table 
illustrates the FIGO stage of invasive cancer of the vulva. 
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Table 13. FIGO staging of invasive vulvar cancer 
____________________________________________________________________________ 
Stage 0 
Tis N0 M0 Carcinoma in situ, intraepithelial carcinoma 
 
Stage I 
T1 N0 M0 Tumor confined to the vulva and/or perineum – 2 cm or less in  
   greatest dimension (no modal metastasis) 
   Stage Ia Lesions 2 cm or less in size confined to the vulva or 
     perineum and with stromal invasion no greater than 
1.0 mm* (no modal metastasis) 
Stage Ib Lesions 2 cm or less in size confined to the vulva or 
  perineum and with stromal invasion greater than 1.0 
  mm (no modal metastasis) 
Stage II 
T2 N0 M0 Tumor confined to the vulva and/or perineum – more than 2 cm in  
   greatest dimension (no modal metastasis) 
 
Stage III  Tumor any size with 
T3 N0 M0 (1) Adjacent spread to the lower urethra and/or vagina, or the anus 
   and/or, 
T3 N1 M0 (2) Unilateral regional lymph node metastasis 
T1 N1 M0 
T2 N1 M0 
 
Stage IVa 
T1 N2 M0 Tumor invades any of the following: upper urethra, bladder, 
   mucosa, rectal mucosa, pelvic bone and/or bilateral regional node 
   metastasis 
T2 N2 M0 
T3 N2 M0 
T4 Any N M0 
 
Stage IVb  
Any T Any N M1 Any distant metastasis including pelvic lymph nodes 
____________________________________________________________________________ 
*The depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most 
superficial dermal papilla to the deepest point of invasion.  Adapted from Stehman, 1997, p. 209. 
 
 This chapter covered in detail the natural history of both vaginal and vulvar cancers, as 
well as other details that include prior research.  The highlights of the history of screening 
protocols by professionals and governmental organizations illustrate the experience that has 
resulted in current screening recommendations. 
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CHAPTER 3: METHODOLOGY 
Overview of study methodology 
This research project included four major steps in the analysis of data as illustrated in 
Figure 2 below.  First, the data was obtained from the SEER-Medicare program, which included 
both SEER cancer registry data and the linked SEER-Medicare dataset.   Both case and control 
data were formatted, cleaned and imported into a SAS compatible dataset.  Second, cases and 
controls that did not fit the study criteria were excluded.  Third, appropriate vaginal and vulvar 
cancer controls were matched with cases.  Utilizing SAS, frequency tables were produced for 
both cases and controls.  Finally, conditional logistic regression analysis was performed to 
estimate the effect of gynecologic cancer screenings and development of invasive vaginal and 
vulvar cancers utilizing STATA. 
 
  
 
Figure 2: Overview of study methodology 
 
The four major steps will be discussed further in the following sections. 
Data source 
The study was designed to perform analyses to determine whether both Pap smear and 
pelvic examination screenings decrease the risk of invasive vaginal and vulvar cancers in women 
aged 65 or older using a matched case-control design.  These two case-control studies compared 
cases of persons diagnosed with invasive vaginal or vulvar cancers with matched controls 
enrolled in Medicare between the years 1991 through 1999 to determine whether they had a 
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history of screening during the estimated combined duration of the pre-invasive detectable phase 
(PIDP), which occurs prior to the occult invasive phase (OIP).     
In an effort to study the efficacy of screening among adults age 65 and older, the 
Surveillance Epidemiology and End Results (SEER)-Medicate data set was utilized.  This 
combined data set links the clinical information from the SEER cancer registries and claims data 
from the Medicare administrative database (Hewitt and Simone, 1999).  The combined SEER-
Medicare data set includes the files PEDSF, SUBDENOM, MEDPAR, NCH and OUTPT.  The 
patient entitlement and diagnosis summary file (PEDSF) includes SEER cancer cases (Engles, et 
al. 2011).  The summarized denominator (SUBDENOM) is the file that contains a five-percent 
(5%) random sample of Medicare recipients living in SEER areas, excluding SEER cancer cases.  
The medical provider analysis and review (MEDPAR) file contains Medicare Part A hospital 
claims.  The national claims history (NCH) file contains Medicare carrier claims from physicians 
and other non-institutional Medicare providers.  The last file that comprises the SEER-Medicare 
data set is the outpatient (OUTPT) file that contains Medicare claims from institutional 
outpatient providers.   
Data for cases 
The SEER-Medicare data set is two linked population-based sources that have been 
merged to provide detailed information about older adults (SEER-Medicare, 2003).   The SEER 
data provided patient-specific information regarding the date of diagnosis, tumor location, grade 
and stage at diagnosis, histological type, as well as patient demographic characteristics such as 
age, gender, race and marital status (Fritz and Ries, 1998); while the Medicare data set provided 
information regarding specific healthcare services utilized by patients covered by Medicare.  The 
SEER-Medicare merged data set provided the screening histories of each case and control prior 
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to diagnosis or reference date.  These matched data sets provided the necessary information to 
perform the analyses for this study. 
Controls were matched to cases on (1) SEER registry (metropolitan regions of Atlanta, 
Detroit, Seattle, San Francisco, Los Angeles; the San Jose-Monterey area; and the states of 
Connecticut, Iowa, New Mexico, Utah and Hawaii) (Warren, et al. 2002, Ries, et al. 2004)); (2) 
age and; (3) reference date (date of diagnosis of case).  The SEER data included information on 
invasive cancer cases from hospitals, laboratories, autopsy reports and death certificates 
(Potosky, et al. 1993). 
Data for controls 
The pool of controls for this study was provided for by the National Cancer Institute and 
was a random five-percent (5%) sample of Medicare beneficiaries residing in the SEER areas 
who did not have cancer during the study time period.  The case and control subjects were made 
up of Medicare beneficiaries enrolled in both Medicare Parts A and B (SEER-Medicare, 2003).  
Medicare Parts A and B are discussed in a subsequent section.  The Medicare database used both 
standard ICD-9 (International Classification of Diseases) procedure coding and HCPCS 
(Healthcare Common Procedure Coding System) coding to record claims made by Medicare 
beneficiaries (Warren, et al. 2002).  
ICD-9 and HCPCS coding system 
ICD-9 and HCPCS coding systems were used to provide information regarding whether 
the case had received a Pap smear or pelvic examination screening during a specific year.  While 
Medicare covered Pap smears every three (3) years for women over the age of 65, pelvic 
examinations were not covered during the study period until 1998.  Until the Balanced Budget 
Act of 1997, pelvic examinations were not covered by Medicare except for patients who were 
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considered high-risk (see Table 14 for definition of high-risk patient) (Bagley and McVearry, 
1998).   The ICD-9 code V15.89 and HCPCS G0101 codes were amended in 1998 to include 
pelvic examinations (NCHS, 2008).  Following is a description of the two coding systems. 
ICD-9 codes 
 The ICD-9 is an international classification system for diseases and healthcare claims, 
and was originally developed by the World Health Organization (Clinical modification (ICD-9-
CM 6th ed.) (NCHS,  2008).  The Medicare Catastrophic Coverage Act of 1988 requires that 
health care professionals provide ICD-9 procedure codes on all Medicare claims (Legislative 
summary: the Family Support Act of 1988) (HCFA, 2012).  The following Table 14 shows the 
ICD-9 codes used for Pap smear screening on Medicare claims (CMS, 1991): 
Table 14. ICD-9 codes for Pap smear screenings 
____________________________________________________________________________ 
ICD-9 codes     Description _____________________________ 
V76.2   Pap screening for malignant neoplasms of the cervix for low-risk 
   patients 
____________________________________________________________________________ 
V76.47  Pap screening for malignant neoplasm, vagina  
____________________________________________________________________________ 
V76.49  Pap screening for malignant neoplasm, other sites 
____________________________________________________________________________ 
V72.31  Pap screening for malignant neoplasm of the cervix, exclusively in 
   conjunction with a full gynecological examination (including 
   pelvic examinations) 
____________________________________________________________________________ 
V15.89  Pap screening for malignant neoplasms of the cervix for high- 
   risk patients.  Medicare considers the following activities: 
1. early onset of sexual activity (under age 16) 
2. multiple sexual partners (> 5 in a lifetime) 
3. history of sexually transmitted disease, including HIV 
4. fewer than three negative Pap smears within the previous 
seven years  
5. exposure to DES (diethylstilbestrol) while in utero (i.e., 
patient is a daughter of a mother who was exposed to DES) 
____________________________________________________________________________ 
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HCPCS codes 
 
 Each carrier claim (services provided by health care professionals such as a pelvic 
examination) included a Healthcare Common Procedure Coding System (HCPCS) to describe 
the nature of the billed service (Buck, 2012).  The HCPCS is composed primarily of Current 
Procedural Terminology (CPT) codes developed by the American Medical Association (AMA), 
with additional codes specific to the Health Care Financing Administration (HCFA) (now known 
as Centers for Medicare and Medicaid Services (CMS)).  The HCPCS was developed in 1983, 
and used by healthcare professionals to bill Medicare for claims made on behalf of beneficiaries 
for services such as clinical procedures, supplies and other healthcare professionals.  In order to 
distinguish between the ICD-9 codes and HCPCS codes, HCPCS describes the health care 
procedure in more detail.  The following Table 15 shows the HCPCS codes used for Medicare 
claims for Pap smear screening: 
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Table 15. HCPCS codes for Pap smear screening tests 
______________________________________________________________________________ 
HCPCS code     Description 
______________________________________________________________________________ 
G0101   Pap cervical or vaginal cancer screening; unspecified (Balanced Budget of 1997, 
   required that Medicare cover both pelvic examinations and breast examinations.  
G0101 coding was further defined to include both pelvic and breast  
examinations.  This policy was instituted in January, 1998). 
 
G0123   Pap screening cytopathology, cervical or vaginal (any reporting system),  
   collected in preservative fluid, automated thin layer preparation; screening by 
cytotechnologist under physician supervision. 
 
G0124   Pap screening cytopathology, cervical or vaginal (any reporting system, 
   collected in preservative fluid, automated thin layer preparation; screening 
   by cytotechnologist under physician supervision; requiring interpretation  
by physician. 
 
G0141   Pap screening cytopathology smears, cervical or vaginal, performed by  
   an automated system, with manual rescreening, requiring supervision by  
a physician. 
 
G0143   Pap screening cytopathology smears, cervical or vaginal, (any reporting 
system), collected in preservative fluid, automated thin layer preparation; with manual 
screening and rescreening by cytotechnologist under supervision by a physician. 
 
G0144   Pap screening cytopathology smears, cervical or vaginal, (any reporting 
system), collected in preservative fluid, automated thin layer preparation; with screening 
by automated system, under supervision by a physician. 
 
G0145   Pap screening cytopathology smears, cervical or vaginal (any reporting 
system), collected in preservative fluid, automated thin layer preparation; with screening 
by automated system and manual rescreening under physician supervision. 
 
G0147 Pap screening cytopathology smears, cervical or vaginal, performed by an automated 
system under physician supervision. 
 
G0148   Pap screening cytopathology smears, cervical or vaginal performed by an 
   automated system with manual rescreening. 
 
P3000   Screening Papanicolaou smear, cervical or vaginal, up to three smears, by 
   technician under physician supervision. 
 
P3001   Screening Papanicolaou smear, cervical or vaginal, up to three smears, by  
   technician under physician supervision, requiring interpretation by physician. 
 
Q0091   Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical 
   or vaginal smear to laboratory. 
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A pelvic examination and Pap smear screening are used to screen for the detection of 
abnormal cancer cells.  The ICD-9 and HCPCS codes were used to create dichotomous variables 
to determine whether cases and controls had received a Pap smear and/or pelvic examination 
screening during a particular year.   
Data cleaning 
 Once the ICD-9 and HCPCS coding schemes were applied to both cases and controls, the 
data were cleaned.  Typographical errors were corrected (such as the letter “O” where the 
number “0” should have been) and cross-checking zip code data with state data (as well as other 
demographic information). 
Phase 1: Exclusion of ineligible cases and controls 
Cases and controls that did not meet the study criteria were excluded.  This study 
originally included 632 and 2,195 cases of vaginal and vulvar cancers, respectively identified 
from the SEER-Medicare data set.  Thereafter, the data were cleaned to correct typographical 
errors, zip-code, state data and any other corrections that were deemed necessary.  The rationale 
for exclusion is that in order to determine the efficacy of screening in older women, only those 
women age 65 and over were included.   
Study criteria exclusion for cases included: 
 Age that was less than 65 years and greater than 100 years 
 HMO coverage during the duration of the study period (excluded because non-Medicare 
HMOs do not track claims/billing data) 
 Did not subscribe to both Medicare Parts A and B coverage during the duration the study 
period 
 Cancers that were not histologically confirmed 
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 Diagnoses of in situ cancer 
 Primary histological subtype was melanoma   
Study criteria exclusion for controls included: 
 Age that was less than 65 years and greater than 100 years  
 Did not subscribe to both Medicare Parts A and B coverage during the duration of the study 
period 
 Missing residential geographical information 
Since Medicare coverage extends to younger individuals who have a disability or end-
stage renal disease, these younger women were excluded from this study.  The study also 
excluded study subjects who did not subscribe to both Medicare Parts A and B.  Medicare Part A 
provides coverage for both inpatient hospital care and skilled nursing facility care, while 
Medicare Part B provides coverage for private physician care and outpatient care. 
Medicare Part A is provided to all qualified beneficiaries.  Part A of Medicare provides 
coverage for inpatient care in short and long-term care facilities, skilled nursing facilities and 
home health or hospice care (Warren, et al. 2002).  Medicare Part B is a voluntary option offered 
to all Part A eligible Medicare beneficiaries that provides coverage of physician services, 
outpatient care, durable medical equipment and some home health services (Warren, et al. 2002).  
It was important that study subjects subscribed to both Medicare Parts A and B based on the 
claims of services beyond that of Part A coverage of primarily inpatient care, in order to detect 
the history of previous Pap smear and pelvic examination screenings. 
Since the aim of this study was to determine the efficacy of both pelvic examination and 
Pap smear screening in the reducing the risk of invasive vaginal and vulvar cancers, cases 
diagnosed with in situ cancers were excluded. The aim of screening is to detect in situ cancers 
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and additional dyplastic conditions.  This study was designed to investigate the efficacy of 
preventive screenings in preventing the invasive disease rather than detecting pre-invasive 
disease.   
Since both cases and controls were matched on population-based SEER registry, it was 
necessary to exclude those controls with missing residential geographical information.  
Phase 2: Matching controls to cases 
After excluding subjects that did not meet the study criteria, the controls were matched to 
cases.   This study randomly matched eight or fewer controls with cases.  It is important that 
case-control designs constitute a representative sample from the control population (McNeil, 
1996).  As mentioned in the data source section, there were four variables on which controls 
were matched to cases:  
 SEER registry 
 Age 
 Length of time in Medicare Part B coverage 
 Date of diagnosis of the case/control   
The first variable is a categorical variable SEER registry which was matched to eliminate 
confounding by geographical location of residence.    
The second covariate, age, is a continuous variable ranging from 65 through 100 years 
which is related to the incidence of vaginal and vulvar cancers.   We utilized Kupper’s caliper 
matching method.  Since it would be difficult to match controls with an “exact” age match to 
cases, caliper matching allowed for cases and controls to be matched within a range of plus or 
minus two years (Kupper, 1998).   
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The third matching variable, reference date, is neither continuous nor categorical.  This 
variable was used in matching to ensure that both cases and controls had a similar period of 
observation.  Controls were matched to cases that had screening data over the same 
chronological period (cf. Weiss, 2006).  This further ensures that cases and respective controls 
were followed for a similar number of years.   
 The matching procedures utilized the SAS statistical software package (SAS, 2005) to 
perform the data management to match controls to respective cases using algorithms and code to 
match controls to cases (Mounib and Satchi, 2000).   The algorithms and code were used to 
construct the matched case/control data sets.  The algorithms developed by Mounib and Satchi 
(2000) used the "without-replacement" technique to ensure that up to eight controls were 
matched to only one case.   
Frequency tables 
Once the data were cleaned and controls matched to cases, frequency tables were 
generated.  Utilizing SAS, comparisons between cases and controls were made with respect to 
race, age, geographical location, income, and education.  In order to classify income and 
education, they were changed into categorical variables so that analysis could be done.  Each 
variable (income and education in the patient’s zip code area) were divided into quartiles of 25%, 
50%, 75% and 100% of the frequency in controls.   
The SEER-Medicare data set has seven different race categories that include: white, 
black, Asian, Hispanic, North American Native, other and unknown.  Since both vaginal and 
vulvar cancers are rare cancer sites, the race categories were combined even further by 
maintaining white and black races, while other races included Asian, Hispanic, North American 
Native, other and unknown races were included in the “other” race category.   
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Phase 3: Conditional logistic regression - analysis of association with screening tests 
 
  Conditional logistic regression was the third phase.  The steps were as follows: 
 
 
 
Figure 3: Overview of conditional logistic regression phase 
 
 Conditional logistic regression models were utilized to assess whether the presence of 
screening measures is effective in reducing invasive vaginal and vulvar cancer.   
Step 1: Exclude screening tests outside PIDP interval 
 Once case-control matching was performed, screening histories of all subjects were 
assessed and screening tests that were in the pre-invasive detectable phase (PIDP) were classified 
as exposed.  Weiss (1999) suggests there is a natural history of cancer development wherein, 
during the pre-invasive detectable phase (PIDP) "changes occur in a particular tissue that 
predispose to the development of cancer” (p. 102).  It is during this time frame (PIDP) when 
screening tests are effective for determining a precursor cancer lesion (i.e., vulvar intraepithelial 
neoplasia or vaginal intraepithelial neoplasia).  It is also necessary to exclude screening tests that 
were performed after an invasive cancer has occurred (OIP, the occult invasive phase) (Weiss, 
1999).  The rationale is that before the PIDP interval, the pre-cancerous lesion cannot be 
detected, thus the benefit of screening cannot be assessed.  Similarly, screening tests performed 
after the lesion has become invasive cannot provide information about the benefit of screening 
(OIP).   These changes may be present for a specific time period (i.e., years in the case of vaginal 
and vulvar cancers) (Figure 4).  The nature of screening is to prevent invasive late stage disease. 
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Adapted from David Maduram MD/PhD, University of Illinois,  
“An analysis of the efficacy of cervical cancer screening in elderly women”, 2009 
   
Figure 4: Exclusion of screening tests before PIDP and after OIP and screening tests that 
occurred between 2 and 7 years from date of diagnosis 
 
 Conditional logistic regression was used to analyze the protective effects of screening 
(Pap smears and pelvic examinations) and whether the presence of screening is effective in 
reducing the incidence of invasive vaginal and vulvar cancers.  Figure 4 illustrates the practical 
implementation of screening test exclusion utilizing an OIP duration of two (2) years and PIDP 
duration of five (5) years.  Population-based cervical cancer data were originally utilized by 
Weiss (1999) to calculate the OIP of two (2) years and PIDP of five (5) years for women of all 
ages.  However, because the data utilized for this study was based solely on women in a 
Medicare population who were 65 years of age and older, it is possible that the durations of the 
OIP/PIDP may differ if older women are more likely than younger women to experience more 
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aggressive forms of vaginal and vulvar cancers.  As such, to evaluate the effect of OIP/PIDP 
durations, this analysis examined various durations of the OIP and PIDP to assess difference in 
the estimated screening efficacy of pelvic examination and Pap smear screenings to determine 
the optimal estimated OIP and PIDP intervals. 
The following Table 16 illustrates the combinations that were utilized for this analysis: 
Table 16. Duration of occult invasive phase (OIP) and  
pre-invasive detectable phase (PIDP) 
 
 
 
 
 
 
 
Step 2: Create conditional logistic regression model for presence/absence of screening 
The following regression model was used to test the hypothesis that the presence of 
screening is effective in reducing the incidence of invasive vaginal and vulvar cancers.   
Regression model 
 The regression model was designed to assess whether Pap smear and pelvic examination 
screening reduces the risk of invasive vaginal and vulvar cancers.  The following Table 17 
illustrates the dependent and primarily independent variables in the model. 
 
  
Duration of 
OIP (years) 
Duration of 
PIDP (years) 
1 4 
1 5 
1 6 
2 4 
2 5 
2 6 
3 4 
3 5 
3 6 
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Table 17. Conditional logistic regression model:  
dependent and independent variables 
Variable type Variable Coding 
Dependent Case-control status 1=case (i.e., disease present) 
  0=control (i.e., disease absent 
Primary independent Screening (during PIDP) 1=screened 
  0=not screened 
 
 As Table 17 indicates the first independent variable describes the screening status of the 
subject during the PIDP.  This particular dichotomous variable score “1” indicates that the 
subject was screened during the PIDP, while “0” indicates that the subject was not screened 
during the PDIP.  Table 18 illustrates the potential confounding variables. 
Table 18. Potential confounding variables 
Variable Description Coding 
Race White Dummy variable coding (Table 6) 
 Black  
 Other (Other, Asian, Hispanic, 
North American Native, 
Unknown) 
 
   
Income Median household income Dummy variable coding: 
 of patient’s zip code region  0=1st income quartile (0-24%) 
   1=2
nd
 income quartile (25-49%) 
   2=3
rd
 income quartile (50-74%) 
   3=4
th
 income quartile (75-100%) 
Based on control values 
   
Education % individuals in patient’s zip Dummy variable coding: 
 code region without high   0=1
st
 education quartile (0-24%) 
 school or other education  1=2
nd
 education quartile (25-49%) 
   2=3
rd
 education quartile (50-74%) 
   3=4
th
 education quartile (75-100%) 
Based on control values 
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The above Table 18 illustrates the variable race as a categorical variable that is used to 
control for the potential confounding effects of race.  The race “white” was used as the baseline 
for race and is dummy coded as follows: 
Table 19. Coding for testing race as a potential confounder 
 Race-based dummy variable 
Race Race 1 Race 2  
White 0 0  
Black  1 0  
Other 0 1  
 
In addition to race, income and education are also potential confounders.  Testing for the 
significance will add precision to the estimates if variables are statistically significant.  The 
categorical variables income and education are based on quartiles of median household income 
and education levels present in the control population zip code areas. 
Step 3: Test for confounding and interaction 
  Hosmer and Lemeshow (2000) suggest that the additional independent variables, 
discussed in the previous paragraph allow for statistical adjustment of potential differences in the 
distribution of the data.  Further, Hosmer and Lemeshow (2000), suggest that epidemiologists 
use the term confounder to describe a covariate that is associated both with the outcome variable 
of interest (i.e., invasive disease) and the primary independent variable (i.e., absence/presence of 
screening).  An interaction is described as the presence of a difference in an association between 
a risk factor and an outcome variable in different levels of a potential effect modifying variable 
(interaction).   
Confounding 
 Case-control studies require some sort of statistical control in their design or analysis in 
order to strengthen the validity of conclusions (Breslow, 2005).  “A confounder is an extraneous 
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factor(s) that may account for the observed effect of risk on disease.” (Hosmer and Lemeshow, 
2000, p. 70).  In this study potential confounders such as income, education and race may need to 
be controlled for in order to make valid inferences on the exposure of interest (screening).  In 
effect, potential confounders can have the potential to over or under estimate the primary 
independent variable and its association with the outcome variable (i.e., diagnosis of vaginal or 
vulvar cancer) (Rothman and Greenland, 2008). 
 Hosmer and Lemeshow (2000) suggest two ways of estimating the impact of a potential 
cofounder.  The first is that the importance of the potential confounder can be assessed by 
determining whether there is an important change in the magnitude of the odds ratio for the 
primary independent variable (screening) between a logistic regression model fit without the 
potential confounder and a logistic regression model fit with the potential confounder (Hosmer 
and Lemeshow, 2000, Rothman and Greenland, 2008).   The second step is to test the 
significance of the variable to see whether it affected the precision of the overall maximum 
likelihood estimate between a logistic regression model fit without the potential confounder and 
a logistic regression model fit with the potential confounder (Hosmer and Lemeshow, 2000).  
Both of these options were performed.   
 Confounding was first assessed by determining whether the inclusion of the potential 
confounder causes a substantial percentage change (> 5%) in the odds ratio of the primary 
independent variable.  The odds ratio percentage change assessment does not determine 
statistical significance, but serves to determine whether a variable may be confounding.  Next, 
the significance of the confounding variable was tested, utilizing the likelihood ratio test, and to 
assess the effect of the variable on the overall goodness of fit of the regression model.  Each 
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potential confounder was incrementally added to the model, and tested for statistical significance 
to assess its role in increasing the precision of the estimate.    
 The CLOGIT procedures in the STATA statistical package were utilized to test the 
importance of the potential confounders. 
Interaction  
 Once the confounders and significant variables were identified, the next step was to 
determine whether there is interaction among the variables.  Epidemiologists use the term “effect 
modifier” to describe a covariate that interacts with a risk factor (Hosmer and Lemeshow, 2000).  
Effect modification occurs when association differs in different strata (e.g., age groups, 
education levels).  It is important for the model to test for interactions that may potentially exist 
because interactions tend to significantly distort the parameter estimates of the independent 
variables (screening in the case of this study) in the model. 
 Effect modification or interaction is explored by creating an interaction variable equal to 
the product of the effect-modifying covariate and risk factor and by assessing the significance of 
the interaction when added to the full logistic model (Hosmer and Lemeshow, 2000).  Effect 
modification can also be examined by stratification, but is not always practical in a matched 
study if the modifier has not been matched on (Kleinbaum, et al. 2003).  The following Table 20 
lists the potential model interaction variables. 
Table 20. Model interaction variables 
 
Interaction Variable 
Screening X Income 
Screening X Race 
Screening X 
Screening X 
Education 
Age 
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 This step in the model building process determined which interaction terms should be 
included in the model.  Table 20 lists potential model interactions tested.  Each interaction was 
added one at a time to the main effects model.  The likelihood ratio test for the interactions terms 
was tested for significance to determine the most significant interaction term that should be 
included in the model.   The difference between the two LR χ2 values is the difference of the χ2 
and degree(s) of freedom using Excel’s CHIDIST formula command to determine the LRT p-
values.  
 The model interactions illustrated in Table 20 can be tested according to Hosmer and 
Lemeshow (2000) by testing the significance of the p-value of the interaction term at the alpha-
level of 0.05.   I tested for the multiplicative interaction among the covariates in the model.  
Based on earlier findings, potential interaction effects were tested (1) screening, race and income 
(vulvar cancer) and (2) screening, race and college education (vaginal cancer).  As such, 
interaction variables were created between these variables utilizing STATA, and conditional 
logistic regression including these terms was executed.   
Efficacy of screening 
 Once the final model was determined, whether the efficacy of screening remained 
constant within specific stratums of the population was investigated.  Screening efficacy was 
studied with respect to age, race, cancer stage and histological type.   
Step 4: Assess effect of screening in total population 
Stratified regression analysis 
 The level of potential confounding and interactions in both cases and controls were 
tested, and the overall efficacy of screening was determined.  Specific groups of cases (i.e., with 
localized, regional, distant cancers) were stratified to estimate the efficacy of screening 
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differences for stages of invasive disease.  Stratified analysis was performed to test whether the 
stratified groups of cases and controls result in unique screening history patterns and if the 
efficacy of screening varies among the various case strata.  Following (Table 21) are the variable 
strata for the stratified regression analysis. 
Table 21. Variable strata for stratified regression analysis 
Variable Case strata  
Cancer stage Localized  
 Regional  
 Distant  
 Unstaged  
   
 Vaginal Vulvar 
Cancer histological types Squamous cell carcinoma  Squamous cell carcinoma 
 Adenocarcinoma  Basal cell 
 Other Paget 
  Other 
 
 The CLOGIT procedure, included in the STATA statistical software package was used to 
perform the stratified regression analysis (StataCorp, 2005). 
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CHAPTER 4: RESULTS 
 
 
 The results of these analyses were performed in three phases as detailed in Chapter 3; (1) 
exclusion of ineligible cases and controls, (2) match controls to cases and (3) conditional logistic 
regression.  The following are the results of these analyses. 
Phase 1: Exclusion of ineligible cases and controls 
 The second step, or Phase 1 of the study, was to exclude those cases and controls that did 
not meet the study criteria.  The following table illustrates the results of exclusionary data. 
 
Table 22. Vaginal and vulvar cancers exclusion criteria for cases 
 
 The base population included 632 vaginal cancer cases and 2,195 vulvar cancer cases.  
There were zero (0) vaginal cases excluded among women younger than 65 years and older than 
100 years and nine (9) vulvar cases that were excluded from this category.  There were 72 
vaginal cancer cases and 220 vulvar cancer cases excluded who were enrolled in an HMO during 
the study period.  There were 31 vaginal cancer cases and 104 vulvar cancer cases not covered 
by both Medicare Parts A and B.  Among cases diagnosed with intermediate behavior or in situ 
disease, 195 vaginal cancer cases and 746 vulvar cancer cases were excluded.  Of vaginal cancer 
  
Cases in population 
after exclusion 
Exclusion criteria Vaginal Vulvar 
  
  
Base population 632 2,195 
Women younger than 65 years old and older than 100 632 2,186 
Enrolled in an HMO during study period 560 1,966 
Not covered by both Medicare Parts A and B 529 1,862 
Diagnosed with intermediate behavior or in-situ disease 334 1,126 
Cancers not histologically confirmed 328 1,108 
Diagnosed “melanoma” 328 1,103 
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cases, six (6) and vulvar cancer cases, eight (8) were excluded whose cancers were not 
histologically confirmed.  Since “melanoma” is not diagnosed among vaginal cancer cases, none 
(0) were excluded; however, there were five (5) vulvar cancer cases excluded.  Finally, there 
were 328 vaginal cancer cases and 1,103 vulvar cancer cases included in this analysis (Table 22). 
Phase 2: Match controls to cases 
 Once the data were cleaned and controls were matched to cases, frequency tables were 
generated.   The following tables were generated based on (1) age, (2) geographic location, (3) 
race, (4) income, (5) education, (6) historic stage and (7) histology. 
Age 
 Age was stratified into five-year age groups in order to generate appropriate frequency 
tables.   
Table 23. Frequency tables for age in cases and controls, vaginal cancer 
    Cases Controls 
Age   Frequency Percentage Frequency Percentage 
65-70   20 6.1 160 6.1 
71-75   52 15.9 416 15.9 
76-80   90 27.4 720 27.4 
81-85   74 22.6 592 22.6 
86-90   53 16.2 424 16.2 
91-95   32 9.8 256 9.8 
96-100   7 2.1 56 2.1 
All Ages   328 100.0 2,624 100.0 
 
 The majority of invasive vaginal cancer cases peaked around the age of 76-80 accounting 
for 27.4% of cases; while there are fewer cases at the youngest age category (6.1%) and the 
oldest age category (2.1%) (Table 23).  Since the controls were matched to cases based on age 
and other variables, the distribution of cases and controls is evenly distributed. 
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Table 24. Frequency tables for age and cases, vulvar cancer 
  Cases Controls 
Age Frequency Percentage Frequency Percentage 
65-70 26 2.4 208 2.4 
71-75 144 13.1 1,152 13.1 
76-80 232 21.0 1,856 21.0 
81-85 276 25.0 2,208 25.0 
86-90 237 21.5 1,896 21.5 
91-95 141 12.8 1,129 12.8 
96-100 47 4.3 376 4.3 
All Ages 1,103 100.0 8,825 100.0 
 
 As illustrated in Table 24, the same strategy of matching controls to cases was applied to 
the vulvar cancer data set.  For invasive vulvar cancer, cases peaked at the 81-85 year age group 
accounting for a quarter (25%) of cases.  The fewest cases were found in the youngest (2.4%) 
and oldest (4.3%) age categories. 
Geographic location 
 Both cases and controls were selected from the eleven geographic locations where SEER 
cancer registries are located.  These areas include the states of Connecticut, Iowa, New Mexico, 
Utah, Hawaii and the metropolitan regions of Atlanta, Detroit, Seattle, San Jose, San Francisco 
and Los Angeles.   
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Table 25. Frequency tables for geographical location in cases and controls,  
vaginal cancer 
 
 The majority of both invasive vaginal cancer cases and controls are from the Detroit 
cancer registry (22.0%), followed by Los Angeles (16.5%), Iowa (12.8%), Connecticut and 
Seattle (both 10.4%), San Francisco (7.3%), Atlanta (6.7%), New Mexico (5.5%), Utah (3.4%), 
Hawaii (2.7%) and San Jose (2.4%) (Table 25).   However, since the controls were matched on 
geographical location the distribution of cases and controls is evenly distributed.   
  
  Cases Controls 
Geographic location Frequency Percentage Frequency Percentage 
Connecticut 34 10.4 272 10.4 
Iowa 42 12.8 336 12.8 
Detroit 72 22.0 576 22.0 
Atlanta 22 6.7 176 6.7 
New Mexico 18 5.5 144 5.5 
Utah 11 3.4 88 3.4 
Seattle 34 10.4 272 10.4 
San Jose 8 2.4 64 2.4 
San Francisco 24 7.3 192 7.3 
Los Angeles 54 16.5 432 16.5 
Hawaii 9 2.7 72 2.7 
All Regions 328 100.0 2,624 100.0 
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Table 26. Frequency tables for geographical location in cases and controls,  
vulvar cancer 
  Cases Controls 
Geographic location Frequency Percentage Frequency Percentage 
Connecticut 189 17.1 1,512 17.1 
Iowa 208 18.0 1,664 18.9 
Detroit 205 18.6 1,640 18.6 
Atlanta 58 5.3 464 5.3 
New Mexico 33 3.0 265 3.0 
Utah 37 3.4 296 3.4 
Seattle 114 10.3 912 10.3 
San Jose 50 4.5 400 4.5 
San Francisco 62 5.6 496 5.6 
Los Angeles 135 12.2 1,080 12.2 
Hawaii 12 1.1 96 1.1 
All Regions 1,103 100.0 8,825 100.0 
 
 The majority of both invasive vaginal cancer cases and controls are from the Detroit 
cancer registry (18.6%), followed by Iowa (18.0%), Connecticut (17.1%), Los Angeles (12.1%), 
Seattle (10.3%), San Francisco (5.6%), Atlanta (5.3%), San Jose (4.5%), Utah (3.4%), New 
Mexico (3.0%) and Hawaii (1.1%) (Table 26).   However, since the controls were matched on 
geographical location the distribution of cases and controls is evenly distributed.   
Race 
 There were not enough cases and controls to analyze the data without the combining of 
race categories.   
Table 27. Frequency tables for race in cases and controls,  
vaginal cancer 
    Cases Controls 
Race   Frequency Percentage Frequency Percentage 
White   261 79.6 2,164 82.5 
Black   46 14.0 233 8.9 
Other   21 6.4 227 8.7 
All Races   328 100.0 2,624 100.0 
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 The majority of invasive vaginal cancer cases (79.6%) are of the white race, followed by 
black (14.0%) and other (6.4%) races (Table 27).   Since controls are matched to cases, similar 
results are found, the majority of controls are of white race (82.5%), black race (8.9%) and other 
(8.7%) races.  There is a higher percent of black women with vaginal cancer (14.0%) than the 
percent of women without vaginal cancer among black women (8.9%).  
Table 28. Frequency tables for race in cases and controls,  
vulvar cancer 
 
 
 
 
 
 The majority of invasive vulvar cancer cases (91.5%) are of the white race, followed by 
black (4.4%) and other (4.2%) races (Table 28).  Once again, since controls are matched to cases, 
similar results are found, the majority of controls are of white race (87.4%), black race (7.2%) 
and other (5.5%) races.  There is a higher percent of white women with vulvar cancer (91.5%) 
than women without vulvar cancers (87.4%). 
Income 
 The following are the frequency distributions of income for both vaginal and vulvar 
cancers based on quartile values. 
  
    Cases Controls 
Race   Frequency Percentage Frequency Percentage 
White   1,008 91.5 7,712 87.4 
Black   48 4.4 632 7.2 
Other   46 4.2 481 5.5 
All Races   1,103 100.0 8,825 100.0 
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Table 29. Frequency tables for median income in cases and controls,  
vaginal cancer 
    Cases Controls 
Income   Frequency Percentage Frequency Percentage 
$0-$36,330   109 33.0 656 25.0 
$36,331-$46,757   93 28.0 658 25.0 
$46,758-$59,719   63 19.0 655 25.0 
$49-720-$200,001   63 19.0 655 25.0 
All Income   328 100.0 2,624 100.0 
 
 The majority of invasive vaginal cancer cases are in the lowest median quartile (33.0%) 
suggesting that lower income is associated with invasive disease (Table 29).  Further, invasive 
vaginal cases based on income are followed by the second lowest median quartile (28.0%), third 
median quartile (19.0%) and fourth median quartile (19.0%), illustrating that as income 
increases, invasive vaginal cancer decreases.   
Table 30. Frequency tables for median income in cases and controls,  
vulvar cancer 
 
 
 
 
 
 The majority of invasive vulvar cancer cases are found in the second and third median 
quartiles (27.0% and 27.0%, respectively), followed by the lowest median quartile (26.0%) and 
the highest median quartile (20.0%).  Although the first three quartiles are very similar in 
number of cases, at the highest income invasive vulvar cancer frequency decreases indicating 
that as income rises, the frequency of invasive disease decreases.   
  
    Cases Controls 
Income   Frequency Percentage Frequency Percentage 
$0-$37,189   284 26.0 2,212 25.0 
$37,190-$46,838   295 27.0 2,210 25.0 
$46,839-$60,030   300 27.0 2,200 25.0 
$60,031-$200,001   224 20.0 2,203 25.0 
All Income   1,103 100.0 8,825 100.0 
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Education 
 The following are the results of education for both vaginal and vulvar cancers based on 
these quartile values. 
Table 31. Frequency tables for education,  
vaginal cancer 
 
The results in Table 31 suggest that low educational level is associated with vaginal 
cancer.  At the lowest education level, the “less than high school” category (23.4%-100.0% 
level), 37% of women had invasive vaginal cancer.  However, it is also important to note, that in 
 
Cases Controls 
 
Frequency Percentage Frequency Percentage 
Less than high school: 
 0.0%-9.2%   56 17.0 657 25.0 
 9.3%-14.4%   67 20.0 656 25.0 
 14.5%-23.3%   85 26.0 655 25.0 
 23.4%-100.0%   120 37.0 656 25.0 
      High school: 
      0.0%-18.5%   56 17.0 656 25.0 
 18.6%-25.4%   89 27.0 656 25.0 
 25.5%-32.4%   94 29.0 658 25.0 
 32.5%-100.0%   23 27.0 654 25.0 
      Some college: 
      0.0%-25.0%   84 26.0 656 25.0 
 25.1%-28.9%   88 27.0 658 25.0 
 29.0%-32.8%   79 24.0 657 25.0 
 32.9%-100.0%   77 23.0 653 25.0 
      College: 
      0.0%-15.0%   118 36.0 655 25.0 
 15.1%-24.1%   91 28.0 657 25.0 
 24.2%-38.1%   58 18.0 656 25.0 
 38.2%-100.0%   61 19.0 656 25.0 
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the lowest level of four years or more of college education level there were 36% of women with 
invasive vaginal cancer.   
Table 32. Frequency tables for education,  
vulvar cancer 
 
 As Table 32 suggests, invasive vulvar cancer frequency cases are fairly evenly distributed 
among all educational levels.  However, in the lowest education level, the “less than high school” 
(20.4%-100.0%) category, 28% of women had invasive vulvar cancer.  In the highest education 
category (four years or more of college), 28% of women were in the lowest quartile.   
  
    Cases Controls 
 
Frequency Percentage Frequency Percentage 
Less than high school: 
 0.0%-9.3%   238 22.0 2,203 25.0 
 9.4%-13.9%   281 25.0 2,212 25.0 
 14.0%-20.3%   270 24.8 2,206 25.0 
 20.4%-100.0%   313 28.0 2,204 25.0 
      High school: 
      0.0%-19.2%   263 24.0 2,204 25.0 
 19.3%-26.6%   259 23.0 2,213 25.0 
 26.7%-33.7%   291 26.0 2,206 25.0 
 33.8%-100.0%   290 26.0 2,202 25.0 
      Some college: 
      0.0%-25.0%   282 26.0 2,227 25.0 
 25.1%-28.7%   280 25.0 2,212 25.0 
 28.8%-32.7%   274 25.0 2,197 25.0 
 32.8%-100.0%   267 24.0 2,189 25.0 
      College: 
      0.0%-15.1%   311 28.0 2,214 25.0 
 15.2%-23.5%   269 24.0 2,207 25.0 
 23.6%-38.3%   278 25.0 2,202 25.0 
 38.4%-100.0%   245 22.0 2,202 25.0 
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Cancer historic stage and histology 
 The SEER-Medicare dataset for vaginal and vulvar cancer cases provided several 
descriptive variables about the nature of the tumor, including cancer historic stage and histologic 
type.   The following Tables 33 and 34 show the results of the frequency tables for both historic 
stage and histologic type in vaginal cancer. 
Table 33. Frequency tables for historic stage in cases,  
vaginal cancer 
Historic Stage Frequency Percentage 
Localized 114 34.8 
Regional 84 25.6 
Distant 55 16.8 
Unstaged 75 22.9 
 
 
 Table 33 suggests that invasive vaginal cancer is diagnosed more commonly among the 
localized historic stage of disease (34.8%), followed by regional (25.6%), unstaged (22.9%) and 
distant (16.8%) of invasive disease cases.   
Table 34. Frequency tables for histological type in cases,  
vaginal cancer 
Histological Type Frequency Percentage 
Adenocarcinoma 29  8.8 
Squamous cell carcinoma 242 73.8 
Other histologies* 57 17.4 
*Carcinomas, NOS, other specific carcinomas 
 
 As the above Table 34 shows 73.8% of invasive vaginal cancer was of the squamous cell 
carcinoma histological type, with “other histologies” and adenocarcinoma accounting for 17.4% 
and 8.8% respectively. 
 The following Tables 35 and 36 present the results of the frequency tables for historic 
stage and histological type in cases for vulvar cancers. 
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Table 35. Frequency tables for historic stage in cases,  
vulvar cancer 
 
 
 
  
 The majority of cases in the study were diagnosed at the localized historic stage of vulvar 
cancer (61.7%), followed by regional (27.5%), distant (4.1%) and unstaged (6.8%) disease 
(Table 35). 
Table 36. Frequency tables for histologic type in cases,  
vulvar cancer 
Histological type Frequency Percentage 
Squamous cell carcinoma 807 73.2 
Basal cell carcinoma 129 11.7 
Paget disease 127 11.5 
Other histologies* 40  3.6 
*Carcinoma, NOS, other specified types 
 
 Table 36 shows that squamous cell carcinoma was by far the most common histological 
type for invasive vulvar cancer, followed by basal cell carcinoma (11.7%), Paget disease (11.5%) 
and “other histologies” (3.6%). 
Phase 3: Conditional logistic regression 
 After generation of frequency tables, four steps were performed in phase 3 of the 
analysis: (1) exclusion of screening tests outside the PIDP interval; (2) creation of conditional 
logistic regression models for presence/absence of screening; (3) testing for confounding and 
interaction; and (4) assessing protective effect of screening in total population. 
 
  
Historic stage Frequency Percentage 
Localized 680 61.7 
Regional 303 27.5 
Distant 45  4.1 
Unstaged 75  6.8 
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Step 1: Exclude screening tests outside the PIDP interval 
 Screening histories of both cases and controls were assessed.  Screening tests that were in 
the pre-invasive detectable phase (PIDP) were included (see Figure 1, Chapter 3).  Several 
combinations of OIP and PIDP were analyzed.  The OIP of two (2) years and PIDP of five (5) 
was determined for both vaginal and vulvar cancers.  The combination captures the majority of 
cases who have invasive vaginal or vulvar cancers and excludes screening histories that were 
likely to have been done for the purpose of diagnoses in response to symptoms or signs of 
disease.  The combination includes only those histories that were done for screening purposes 
(Weiss, 1999). 
Step 2: Create conditional logistic regression model for presence/absence of screening 
 First, the unadjusted estimates were analyzed along with a test for trends.  The following 
Tables 37 and 38 show the results of this analysis.
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Table 37. Vaginal cancer unadjusted estimates
  Cases Controls  
Variable  Frequency Percentage Frequency Percentage OR 95% CI 
Screening status Screened 48 14.6 464 17.7 0.79 0.57-1.11 
 Unscreened 280 85.4 2,160 82.3   
        
Race White 261 79.6 2,164 82.5 1.00  
 Black 46 14.0 233 8.9 1.72 1.20-2.46 
 Other 21 6.4 227 8.7 0.69 0.41-1.17 
        
Income $0-$36,330 109 33.0 656 25.0 1.00  
 $36,331-$46,757 93 28.0 658 25.0 0.84 0.62-1.13 
 $46,758-$59,719 63 19.0 655 25.0 0.54 0.38-0.75 
 $59,720-$200,001 63 19.0 655 25.0 0.50 0.35-0.72 
      (p = 0.00001) 
Less than  0-0.0972 56 17.0 657 25.0 1.00  
 high school 0.0973-0.14954 67 20.0 656 25.0 1.17 0.82-1.68 
 0.14955-0.2298 85 26.0 655 25.0 1.38 0.97-1.97 
 0.2299-1 120 37.0 656 25.0 2.18 1.56-3.04 
      (p =0.0000001) 
High school 0-0.19 56 17.0 656 25.0 1.00  
 0.25226-0.2893 89 27.0 656 25.0 1.47 1.04-2.08 
 0.2894-0.3286 94 29.0 658 25.0 1.99 1.34-2.94 
 0.3287-1 23 27.0 654 25.0 1.92 1.24-2.96 
      (p =0.001) 
Some college 0-0.25225 84 26.0 656 25.0 1.00  
 0.25226-0.2893 88 27.0 658 25.0 1.07 0.77-1.48 
 0.2894-0.3286 79 24.0 657 25.0 0.95 0.67-1.34 
 0.3299-1 77 23.0 653 25.0 0.91 0.63-1.31 
      (p = 0.522) 
College 0-0.15161 118 36.0 655 25.0 1.00  
 0.15162-0.22675 91 28.0 657 25.0 0.78 0.57-1.06 
 0.22676-0.37065 58 18.0 656 25.0 0.47 0.33-0.66 
 0.37066-1 61 19.0 656 25.0 0.46 0.32-0.65 
      (p = 0.00000002) 
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 The univariate or unadjusted estimates model allows analysis of a single variable.  The 
above Table 37 (vaginal cancer) presents finding for the variables race, income, education (less 
than high school, high school, some college and college) for vaginal cancer cases and controls.  
The trends test suggests that income, less than high school education, high school education and 
college are statistically significant at the p<0.05 level.   
 The unadjusted estimates model suggests that overall screening status (everpap) 
decreases the risk of invasive vaginal cancer when screening is performed (OR 0.79, 95% CI 
0.57-1.11), but these results are not statistically significant (Table 37).  Regarding income, 
significant results are found in the third and fourth income quartiles (OR 0.54, 95% CI 0.38-0.75 
and OR 0.50, 95% CI 0.35-0.72, respectively); test for trend is also significant at the p<0.05 
level.  Invasive disease is related to lower socio-economic status. 
 Significant results are also found among invasive vaginal cancer cases in the third and 
fourth quartiles of more than four years of college education (OR 0.47, 95% CI 0.33-0.66 and 
OR 0.46, 95% CI 0.32-0.65, respectively); test for trends is also significant at the p<0.05 level.  
Again, these findings, while unadjusted, suggest that invasive vaginal cancer is related to low 
socio-economic status.   
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Table 38. Vulvar cancer unadjusted estimates 
  Cases Controls   
Variable  Frequency Percentage Frequency Percentage OR 95% CI 
Screening status Screened 218 19.8 1,588 18.0 1.13 0.95-1.33 
 Unscreened 885 80.2 7,236 82.0   
        
        
Race White 1,008 91.5 7,712 87.4 1.00  
 Black 48 4.4 632 7.2 0.56 0.41-0.76 
 Other          46 4.2 481 5.5 0.69 0.50-0.97 
        
Income $0-$37,075 284 26.0 2,212 25.0 1.00  
 $37,076-$46,467 295 27.0 2,210 25.0 1.06 0.89-1.27 
 $46,468-$59,703 300 27.0 2,200 25.0 0.99 0.82-1.19 
 $59,704-$200,001 224 20.0 2,203 25.0 0.76 0.62-0.93 
      (p = 0.009) 
Less than  0-0.09384 238 22.0 2,203 25.0 1.00  
 high school 0.09385-0.14084 281 25.0 2,212 25.0 1.23 0.82-1.68 
 0.14085-0.2071 270 24.8 2,206 25.0 1.17 0.97-1.97 
 0.2072-1 313 28.0 2,204 25.0 1.33 1.56-3.04 
      (p = 0.008)  
High school 0-0.1927 263 24.0 2,204 25.0 1.00  
 0.1928-0.2670 259 23.3 2,213 25.0 1.02 0.58-1.24 
 0.2671-0.3385 291 26.0 2,206 25.0 1.19 0.97-1.47 
 0.3386-1 290 26.0 2,202 25.0 1.24 0.98-1.48 
      (p = 0.035) 
Some college 0-0.2507 282 26.0 2,227 25.0 1.00  
 0.2508-0.2875 280 25.0 2,212 25.0 1.00 0.84-1.19 
 0.2876-0.3275 274 25.0 2,197 25.0 0.99 0.82-1.19 
 0.3376-1 267 24.0 2,189 25.0 0.94 0.77-1.15 
      (p = 0.571) 
College 0-0.1515 311 28.0 2,214 25.0 1.00  
 0.1516-0.2350 269 24.0 2,207 25.0 0.88 0.74-1.05 
 0.2351-0.3823 278 25.0 2,202 25.0 0.90 0.75-1.08 
 0.3824-1 245 22.0 2,202 25.0 0.78 0.64-0.94 
      (p = 0.017) 
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 In the above Table 38 (vulvar cancer), analyses of the variables race, income, education 
(less than high school, high school, some college and college) for vulvar cancer cases and 
controls are presented.  The test for trend shows that income and less than high school are 
statistically significant at the p<0.05 level which may relate to low income and low education 
and their association with greater disease risk.  Furthermore, four or more years of college is also 
statistically significant at p<0.05 level, suggesting that at higher education categories the risk of 
disease is lower. 
 Furthermore, the unadjusted estimates model suggests that overall screening status does 
not decrease the risk of invasive vulvar cancer when screening is performed (OR 1.13, 95% CI 
0.95-1.33) (Table 38).  Significant findings are suggested in the race category, where black (OR 
0.56, 95% CI 0.41-0.76) and “other” races (OR 0.69, 95% CI 0.50-0.97) are significant when 
compared to the reference category.  Significant results are also found in the fourth quartiles of 
more than four years of college education (OR 0.78, 95% CI 0.64-0.94).  These findings suggest 
that in these particular race and education categories, there is a decreased risk of invasive 
disease.  However, these are unadjusted estimates and require further analysis. 
 In the third quartile level of income (OR 0.99, 95% CI 0.82-1.19) as well as in the third 
and fourth quartiles of the some college category (OR 0.99, 95% CI 0.82-1.19 and OR 0.94, 95% 
CI 0.77-1.15) there appears to be no association between the income categories and invasive 
disease.  Findings for the second and third quartiles of four years or more of college (OR 0.88, 
0.74-1.05 and OR 0.90, 95% CI 0.75-1.08, respectively) suggest that the higher the education, 
the lower the risk of invasive disease.    
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Step 3. Test for confounding and interaction 
 After testing the individual variables for significance, a forward selection approach to 
model building was used (Tables 39 and 40).   
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Table 39.  Vaginal cancer forward selection models 
  
  
     
   LRT p-value LRT p-value 
 
Models 
 
OR 
% ∆ 
OR 
(one-sided) 
(everpap only) 
(one sided) 
(everpap and race) 
Everpap only model 0.79    
Everpap and race only model 0.80 -1.12 0.005017  
     
Everpap and race only model 0.80 -1.12   
Everpap, race and income only model 0.83 -4.11  0.00015 
Everpap, race and < high school only model 0.84 -5.93  0.00012 
Everpap, race and high school only model 0.81 -2.10  0.00914 
Everpap, race and some college only model 0.80 -1.25  0.87085 
Everpap, race and college only model 0.84 -5.14  0.00000 
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 The likelihood ratio χ2 test for each parameter estimate was based on comparing two 
logistic models.  The first model in Table 39 is the one with the individual variable included for 
testing and one without it.  In this case the first model is the screening status only model and the 
second is the screening status and race model.   
 When comparing the everpap only model with the everpap and race only model the 
percentage change in odds ratio is calculated, along with the LRT p-value (one-sided) (everpap 
only).  The resulting percentage change in odds ratio is less than five percent (5%) and the 
p<0.05 is significant.  Since the result is significant, the other socio-economic variables with 
everpap and race were tested.   
 Next, income was added to the everpap and race model, then the other socio-economic 
status variables.  The resulting percentage change in odds ratio for all the models is less than five 
percent (5%) and the LRT p-value is not significant for any of the other education variables.  
Therefore, the model with the most significant LRT p<0.05 is “everpap, race and college only 
model”.
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Table 40. Vulvar cancer forward selection models 
     
   LRT p-value LRT p-value 
 
Models 
 
OR 
% ∆ 
OR 
(one-sided) 
(everpap only) 
(one sided) 
(everpap and race) 
Everpap only model 1.13    
Everpap and race only model 1.11 1.90 0.000007  
     
Everpap and race only model 1.11 1.90   
Everpap, race and income only model 1.11 1.62  0.00000 
Everpap, race and < high school only model 1.13 0.18  0.00013 
Everpap, race and high school only model 1.12 1.08  0.07718 
Everpap, race and some college only model 1.11 1.62  0.72626 
Everpap, race and college only model 1.12 0.36  0.00224 
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 For vulvar cancer, the first model tested (Table 40) is the one with the individual variable 
included for testing and one without.  In this case the first model is the screening status only 
model and the second is the everpap and race model.  The LRT and corresponding p-values were 
calculated the same way for vulvar cancer as for analyses of vaginal cancer. 
 The resulting percentage change in odds ratio is less than five percent (5%) for all 
models.  However, for the “everpap, race and income only” and the “everpap, race and less than 
high school only” models are significant at the p<0.05.  Since the result is significant, the other 
socio-economic variables with everpap and race were tested. 
  Next, income was added to the everpap and race model, then the other socio-economic 
variables.  The resulting percentage change in odds ratio for all the models is less than five 
percent (5%) and the LRT p-value is not significant for any of the education variables.  
Therefore, the model with the most significant LRT p-value (p<0.05) is “everpap, race and 
income only model.”  For vulvar cancer, the model “everpap, race and income” was the most 
significant and thus, chosen to test for significance of interaction.  
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Table 41. Vaginal cancer test of significance of interactions 
 Cases Controls    
 Screened Unscreened Screened Unscreened   LRT p-value 
Variable Frequency Percentage Frequency Percentage Frequency Percentage Frequency Percentage OR 95% CI (one-sided) 
Age:            
  65-74 6 1.3 53 11.6 40 8.8 356 72.5 1.02 0.40-2.64  
  75-84 28 1.8 134 8.6 317 20.4 1,078 73.1 0.72 0.47-1.12  
  85-100 14 1.5 93 9.9 104 11.1 729 80.6 1.11 0.59-2.05 0.43823 
            
Race:            
  White 42 1.7 219 9.0 405 16.7 1,759 72.5 0.84 0.60-1.17  
  Black 2 0.7 44 15.8 29 10.4 204 73.1 0.41 0.90-1.83  
  Other 4 1.6 17 6.9 27 10.9 200 80.6 2.18 0.64-7.46 0.18731 
            
College:            
  0.0%-15.1% 20 2.6 98 12.6 92 11.8 567 73.0 1.26 0.73-2.18  
  15.2%-22.6% 9 1.4 74 11.2 94 14.3 481 73.1 0.65 0.31-1.34  
  22.7%-37.0% 7 0.9 56 7.4 150 19.7 548 72.0 0.46 0.21-1.04  
  37.1%-100.0% 12 1.6 52 6.9 125 16.5 567 75.0 1.04 0.53-2.03 0.02072 
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 In the above Table 41, the variable “college” is significant at the p<0.05 level.  Therefore, 
the analyses suggest a significant interaction between the variables “college” and “everpap”.  
There is no significant effect modification between screening status (everpap) and age (p=0.44), 
nor between screening status (everpap) and race (p=0.19).    
 The results in the above table suggest there is no pattern of association between age, race 
and screening status with four (4) years or more of college education and therefore age and race 
are not included in the final model. 
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Table 42: Vulvar cancer test of significance of interactions model 
 Cases Controls    
 Screened Unscreened Screened Unscreened   LRT p-value 
Variable Frequency Percentage Frequency Percentage Frequency Percentage Frequency Percentage OR 95% CI (one-sided) 
Age:            
  65-74 15 1.5 119 11.7 155 15.3 725 71.5 0.57 0.31-1.00  
  75-84 121 2.6 379 8.1 926 19.9 3,227 69.4 1.13 0.90-1.42  
  85-100 82 1.9 387 9.1 511 13.0 3,281 77.0 1.38 1.06-1.80 0.01067 
            
Race:            
  White 207 2.4 802 9.2 1,461 16.8 6,251 71.7 1.11 0.94-1.32  
  Black 7 1.0 41 6.0 73 10.7 559 82.2 1.30 0.56-3.03  
  Other 4 0.8 42 8.0 58 11.0 423 80.3 0.72 0.25-2.09 0.65705 
            
Income:            
 $0-$37,075 55 2.3 221 9.1 335 13.8 1,814 74.8 1.33 0.96-1.84  
 $37,076-$46,467 57 2.3 239 9.7 447 18.2 1,715 69.8 0.92 0.67-1.25  
 $46,468-$59,703 63 2.4 236 9.2 414 16.1 1,860 72.3 1.20 0.88-1.62  
 $59,704-$200,001 43 1.7 189 7.6 396 16.0 1,844 74.6 1.05 0.74-1.50 0.38247 
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 The results in Table 42 shows the variable “age” to be significant at the p<0.05 level 
which indicates a significant interaction between the variable “age” and screening status 
(everpap).  The negative effect of screening status is only seen at the youngest age category (65-
74 years). 
 The results in the above table further suggest that even though there is no significant 
interaction between screening and race, the “other” race category suggests invasive vulvar cancer 
is decreased when screening is performed (OR 0.72, 95% CI 0.25-2.09).  There is no significant 
interaction between screening status and race (p=0.66) or screening and income (p=0.38) (Table 
42).   
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Table 43. Vaginal cancer final model 
  Cases Controls   
Variable  Frequency Percentage Frequency Percentage OR 95% CI p-value 
Screening status Screened 48 14.6 461 17.6 0.84 0.60-1.17 0.297 
 Unscreened 280 85.4 2,163 83.4    
         
Race White 261 79.6 2,164 82.5 1.00   
 Black 46 14.0 233 8.9 1.37 0.94-1.99 0.098 
 Other 21 6.4 227 8.7 0.81 0.34-1.00 0.049 
         
College 0.0%-15.1% 118 36.0 655 25.0 1.00   
 15.2%-22.6% 91 28.0 657 25.0 0.81 0.59-1.10 0.175 
 22.7%-37.0% 58 18.0 656 25.0 0.48 0.34-0.68 0.000 
 37.1%-100% 61 19.0 656 25.0 0.48 0.34-0.68 0.000 
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 The results in Table 43 suggest that the overall risk of invasive vaginal cancer is reduced 
by having pelvic examinations and Pap smear screenings (OR 0.84, 95% CI 0.60-1.17); however, 
these results are not statistically significant.  Thus, our hypothesis that the use of pelvic 
examination and Pap smear screenings is effective in reducing the risk of vaginal cancers in 
women aged 65 and over is not supported.  The results suggest there is no association between 
screening and the risk of invasive vaginal cancer. 
 For the the race category, black (OR 1.37, 95% CI 0.94-1.99) race has a positive 
association with invasive disease.  In addition, older women who have had four (4) years of 
college (0.0%-15.1%) education have a decreased risk of vaginal cancer when compared to the 
reference group (OR 0.81, 95% CI 0.59-1.10; OR 0.48, 95% CI 0.34-0.68 and OR 0.48, 95% CI 
0.34-0.68 respectively), thus indicating a negative association between high socio-economic 
status and invasive disease.  Results are significant for the last two (2) quartiles of college 
education.
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Table 44. Vulvar cancer final model 
  Cases Controls    
Variable  Frequency Percentage Frequency Percentage OR 95% CI p-value 
Screening status Screened 218 19.8 1,592 18.0 1.11 0.94-1.31 0.215 
 Unscreened 885 80.2 7,233 82.0    
         
Race White 1,008 91.5 7,712 87.4 1.00   
 Black 48 4.4 632 7.2 0.47 0.34-0.65 >0.001 
 Other 46 4.2 481 5.5 0.65 0.47-0.91 0.012 
         
Income $0-$37,075 284 26.0 2,212 25.0 1.00   
 $37,076-$46,467 295 27.0 2,210 25.0 0.95 0.79-1.14 0.587 
 $46,468-$59,703 300 27.0 2,200 25.0 0.84 0.69-1.02 0.078 
 $59,704-$200,001 224 20.0 2,203 25.0 0.63 0.51-0.78 <0.001 
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 The results presented in Table 44 refer to the final model in the analysis.  The results 
suggest that the overall risk of invasive vulvar cancer includes a slight positive association 
between disease and having pelvic examinations and Pap smear screenings (OR 1.11, 95% CI 
0.94-1.31); however, the results are not significant. Thus, the hypothesis that use of pelvic 
examination and Pap smear screenings is effective in reducing the risk of vulvar cancers in 
women aged 65 and over is not confirmed.  The results suggest there is no association between 
screening and the risk of invasive vaginal cancer. 
  For race, with white race as a baseline reference, there is a significant negative 
association between invasive disease and black race.  For race, black (OR 0.47, 95% CI 0.34-
0.65) compared whites presents an overall decrease in risk of invasive disease (Table 44).   
 All income category findings suggest that low income is related to the development of 
vulvar cancers.  Compared to the baseline income category, at $37,076-$46,467 (OR 0.95, 95% 
CI 0.79-1.14), $46,468-$57,703 (OR 0.84, 95% CI 0.69-1.02) and the upper income category 
$59,704-$200,001 (OR 0.63, 95% CI 0.51-0.78), these findings show a reduced risk of disease 
with higher income. 
Step 4: Assess effect of screening in total population 
  Assessing the association between screening and invasive vaginal cancer by age and 
college, involved testing for the interaction between age and college education (Table 45).  
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Table 45. Association between screening and invasive vaginal cancer by age, race and college education 
 
 
  
 
 
 
 Screened Unscreened   
 Cases Controls Cases Controls   
Combinations Frequency Percentage Frequency Percentage Frequency Percentage Frequency Percentage OR 95% CI 
Age:           
  65-74 years 6 1.3 40 8.8 53 11.6 356 78.2 1.09 0.42-2.82 
  75-84 years 28 1.8 317 20.4 134 8.6 1,078 69.2 0.72 0.46-1.11 
  85-100 years 14 1.5 104 11.1 93 9.9 729 77.6 1.13 0.61-2.09 
           
Race:           
  White 42 1.7 405 16.7 219 9.0 1,759 72.5 0.86 0.60-1.22 
  Black 2 0.7 29 10.4 44 15.8 204 73.1 0.36 0.08-1.59 
  Other 4 1.6 27 10.9 17 6.9 200 80.7 0.54 0.55-5.85 
           
College:           
   0.0%-15.1% 20 2.6 92 11.8 98 12.6 567 73.0 1.29 0.75-2.23 
   15.2%-22.6% 9 1.4 94 14.3 74 11.2 481 73.1 0.65 0.31-1.34 
   22.7%-37.0% 7 0.9 150 19.7 56 7.4 548 72.0 0.46 0.20-1.05 
   37.1%-100% 12 1.6 125 16.5 52 6.9 567 75.0 1.03 0.53-2.03 
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 The results of the conditional logistic regression analyses performed on age are shown in 
Table 45.  Median age of cases and controls for vaginal cancer was 81.6 years.  There was no 
significant interaction between screening and age.  The results for race suggest that screening is 
effective in all race categories: white OR 0.86 (95% CI 0.60-1.22), black OR 0.36 (0.08-1.59) 
and other races OR 0.54 (0.55-5.85).  However, these results are not significant. 
 The association between screening and invasive vaginal cancer among women with more 
than four (4) years of college education suggests the first (OR 1.29, 95% CI 0.75-2.23) and last 
(OR 1.03, 95% CI 0.53-2.03) tiers of individuals in zip code region are at a slight risk of invasive 
disease compared to the middle two tiers of women in those zip code regions with more than 
four (4) years of college education (OR 0.65, 95% CI 0.31-1.34 and OR 0.46, 95% CI 0.20-1.05, 
respectively) (Table 45).   However, the results are not significant and there is not a pattern of 
interaction with college education.. 
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Table 46. Association between screening and invasive vulvar cancer by age, race and income 
 
 
 
 Screened Unscreened   
 Cases Controls Cases Controls   
Combinations Frequency Percentage Frequency Percentage Frequency Percentage Frequency Percentage OR 95% CI 
Age:           
   65-74 years 15 1.5 155 15.3 119 11.7 725 71.5 0.55 0.31-0.97 
   75-84 years 121 2.6 926 19.9 379 8.1 3,227 69.4 1.11 0.88-1.38 
   85-100 years 82 1.9 511 12.0 387 9.1 3,281 77.0 1.38 1.06-1.79 
           
Race:           
  White 207 2.4 1,461 16.8 802 9.2 6,251 71.7 1.13 0.95-1.33 
  Black 7 1.0 73 10.7 41 6.0 559 82.2 1.41 0.60-3.28 
  Other 4 0.8 58 11.0 42 8.0 423 80.3 0.67 0.23-1.95 
           
Income:           
  $0-$37,075  55 2.3 335 13.8 221 9.1 1,814 74.8 1.36 0.98-1.89 
  $37,076-$46,467 57 2.3 447 18.2 239 9.7 1,715 69.8 0.93 0.68-1.27 
  $46,468-$59,703 63 2.4 414 16.1 236 9.2 1,860 72.3 1.20 0.89-1.62 
  $59,704-$200,001 43 1.7 396 16.0 189 7.6 1,844 74.6 1.05 0.74-1.50 
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 Among younger women, ages 65-74 years, who have been screened a slightly significant 
decreased risk of invasive vulvar cancer is indicated (OR 0.55, 95% CI 0.31-0.97) (Table 46).  
However, for women ages 75 and over there is no association between invasive disease and 
screening.   
 Regarding race, for white (OR 1.13 95% CI 0.95-1.33) and black (OR 1.41 95% CI 0.60-
3.28) races there is no association between screening and invasive disease.  However, for “other” 
(OR 0.67 95% CI 0.23-1.95) race category, there is a decreased risk of invasive disease but the 
findings are not significant. 
 In the income categories, the results suggest that there is no association between 
screening and invasive vulvar cancer. 
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Table 47. Vaginal cancer screening efficacy by stage 
 
 Screened Unscreened   
 Cases Controls Cases Controls   
Historic Stage* Frequency Percentage Frequency Percentage Frequency Percentage Frequency Percentage OR 95% CI 
Localized 22 2.1 161 15.7 92 9.0 751 73.2 1.09 0.65-1.83 
Regional 12 1.6 132 17.5 72 9.5 540 71.4 0.78 0.40-1.51 
Distant 3 0.6 67 13.5 52 10.5 373 75.4 0.31 0.09-1.03 
Unstaged 11 1.6 101 15.0 64 9.5 499 73.9 0.86 0.43-1.70 
*Adjusted for race , age and college 
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  Stratified analyses suggested that Pap smear and pelvic examination screening had a 
stronger negative association with regional OR 0.78 (95% CI 0.40-1.51), distant OR 0.31 (95% 
CI 0.09-1.03) and unstaged OR 0.86 (95% CI 0.43-1.70).  Historic stage vaginal cancer groups 
were found to show reduced risk as opposed to localized cancers OR 1.09 (95% CI 0.65-1.83) 
and were borderline significant for distant stage disease (Table 47). 
 The results indicate partial support for the hypothesis that specific subgroups of cases 
will have unique screening pelvic examination and Pap smear history relationships based on the 
progression of disease (i.e., localized, regional, distant and unstaged cancers); the more advanced 
the disease the more likely that the case has not had sufficient screening. The results suggest that 
screening tests are not effective in reducing the risk of early stage disease but are effective in 
reducing the risk of late stage disease. 
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Table 48. Vulvar cancer screening efficacy by stage 
 
 
 Screened Unscreened   
 Cases Controls Cases Controls   
Historic Stage* Frequency Percentage Frequency Percentage Frequency Percentage Frequency Percentage OR 95% CI 
Localized 156 2.5 951 15.5 524 8.6 4,490 73.4 1.42 1.16-1.73 
Regional 46 1.7 480 17.6 257 9.4 1,944 71.3 0.71 0.51-1.00 
Distant 6 1.5 65 16.0 39 9.6 295 72.8 0.68 0.27-1.70 
Unstaged 10 1.5 96 14.2 65 9.6 504 74.7 0.77 0.37-1.59 
*Adjusted for race , age and income 
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 Similar findings were observed for vulvar cancers where stratified analyses suggested 
that Pap smear and pelvic examination screenings had a stronger negative association with 
regional OR 0.71 (95% CI 0.51-1.00), distant OR 0.68 (95% CI 0.27-1.70) and unstaged OR 
0.77 (95% CI 0.37-1.59) invasive vulvar cancers as opposed to localized stage cancers OR 1.42 
(95% CI 1.16-1.73).  The findings suggested borderline significance for regional stage disease.   
 The findings indicate partial support for hypothesis that specific subgroups of cases will 
have unique screening pelvic examination and Pap smear history relationships based on the 
progression of disease (i.e., localized, regional, distant and unstaged cancers); the more advanced 
the disease the more likely that the case has not had sufficient screening. The results suggest that 
screening tests are not effective in the prevention of early stage disease but are effective in the 
prevention of late stage diseases. 
114 
 
Table 49. Vaginal cancer screening efficacy by histology 
 
 Screened Unscreened   
 Cases Controls Cases Controls   
Histology* Frequency Percentage Frequency Percentage Frequency Percentage Frequency Percentage OR 95% CI 
Adenocarcinoma 9 2.8 41 12.7 27 8.3 247 76.2 1.65 0.64-4.24 
Squamous cell carcinoma 32 1.5 347 15.9 211 9.6 1,597 73.0 0.77 0.51-1.16 
Other 7 1.6 73 16.6 42 9.5 319 72.3 0.70 0.33.1.47 
*Adjusted for race , age and college 
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 The results shown is Table 49 suggest that screening has a negative association among 
squamous cell carcinoma (0R 0.77, 95% CI 0.51-1.16) and other types of invasive vaginal cancer 
(0R 0.70, 95% CI 0.33-1.47) suggesting that screening may prevent the most common type of 
invasive vaginal cancer (squamous cell carcinoma) and other types of invasive disease.  
However, the findings are not significant. 
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Table 50. Vulvar cancer screening efficacy by histology 
 
 
 
 Screened Unscreened   
 Cases Controls Cases Controls   
Histology* Frequency Percentage Frequency Percentage Frequency Percentage Frequency Percentage OR 95% CI 
Squamous cell carcinoma 145 2.0 1,176 16.2 662 9.1 5,281 72.7 0.98 0.81-1.20 
Basal cell carcinoma 31 2.7 155 13.4 98 8.4 877 75.5 1.84 1.17-2.90 
Paget disease 33 2.9 198 17.3 94 8.2 818 71.6 1.53 0.97-2.41 
Other 9 2.5 63 17.5 31 8.6 257 71.4 1.19 0.53-2.66 
*Adjusted for race , age and income 
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 The results presented in Table 50 suggest that screening has no association among 
squamous cell carcinoma (0R 0.98, 95% CI 0.81-1.20) and positive association among basal cell 
carcinoma (OR 1.84, 95% CI 1.17-2.90), Paget disease (OR 1.53, 95% CI 0.97-2.41) and other 
types of invasive vulvar cancer (OR 1.19, 95% CI 0.53-2.66) but the findings are not significant. 
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CHAPTER 5: DISCUSSION 
 
 This discussion chapter will summarize the study’s significant findings and compare 
those findings with the previous literature.  It will note the limitations of the study and offer 
conclusions the findings suggest. 
Significant findings 
 Findings suggest that Pap smear and pelvic examination screenings reduce the risk of 
regional, distant and unstaged invasive vaginal cancer.  Similar findings were observed for 
vulvar cancers suggesting that gynecological screenings reduce the risk of regional, distant and 
unstaged cancer stages.  sdThese findings suggest that screening tests may be effective in the 
reducing the risk of later stages of disease of both vaginal and vulvar cancers. 
 Women aged 65-74 who have been screened have a moderately significant decreased risk 
of invasive vulvar cancer.  This finding suggests that screening is most effective in reducing 
invasive vulvar cancer among women age 65-74 years. 
Comparisons  
 Brinton, et al. (1990a)’s and Parazzini, et al. (1993)’s studies suggest that at least one or 
more Pap smear screenings decrease the risk of invasive vulvar cancer, which is consistent with 
this study’s findings.   
 There are opinion articles and studies that suggest that cervical cancer screening should 
stop at age 50 for women who have had regular Pap tests prior to age 50 with negative results 
(Cruickshank, et al. 1997).  Similarly, other studies suggest that stopping Pap smears screenings 
at age 50 may be more appropriate provided that such women had at least three consecutive Pap 
smears with negative results (Van Wijngaarden and Duncan, 1993, Flannelly, et al. 2004).  
Flannelly, et al. (2004) have further suggested that women with an abnormal Pap smear history 
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should continue screening after 50 years of age.  The findings of this study suggest that 
gynecological screening decreases the risk of late-stage invasive vaginal and vulvar cancers 
among women ages 65 and older. 
 While older women tend to have lower gynecological cancer screening rates in general 
(Ostbye, et al. 2003), continued disagreement exists between professional organizations and 
government review boards with respect to the age related recommendations and guidelines for 
gynecological cancer screening (Sirovich and Welch, 2004a, USPSTF, 2012a).  The findings of 
the present study support Ostbye, et al. (2003) in that women in a Medicare population tend not 
to have consistent screening histories. The study found that 1.6% of vaginal cancer cases, 15.7% 
of vaginal cancer controls, 2.2% of vulvar cancer cases and 16.0% of vulvar cancer controls were 
screened during the PIDP.   
 Walter, et al. (2004), suggest that based on a their study of 5,000 Medicare beneficiaries 
aged 70 and older, physicians may intend to consider health status in determining a patient’s 
eligibility for screening yet screen patients equally regardless of health status.  Older women rely 
on their primary care physician to make the suggestion for screening (Walter, et al. 2004, Blair, 
1998, Sawaya, et al. 2009).  However, while the Walter, et al. (2004) study concluded that even 
though physicians consider health status, they still provide the screen; conversely, other studies 
suggest that there are barriers to cancer screening by providers (Walter, et al. 2004, Blair, 1998).  
These barriers may include the lack of cancer screening guidelines knowledge, lack of 
acceptance of guidelines, patient’s age, comorbidities of patient, time constraints or lack of 
patient compliance (Blair, 1998). This finding is contrary to the findings of this study which 
suggest that older women have low gynecological screening rates.   
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 Another study conducted by Heflin, et al. (2006) surveyed physicians regarding their 
decision to offer screening to women between the ages of 70 and 90 years based on their 
perceived health status.  According to the study, physicians were significantly less likely to offer 
a screening Pap smear to women who were either moderately ill or in frail health compared to 
women in good health (Heflin, et al. 2006).  Older women aged 65 and older may have three or 
more chronic conditions or disabilities.  The three most common include arthritis, cardiovascular 
disease and cancer (Blair, 1998).  Furthermore, the Heflin study also suggests that a history of 
normal Pap smears was associated with a significantly lower likelihood of offering a screening 
Pap smear at an older age (Heflin, et al. 2006).   The results of this study suggest that 
gynecological screening can be beneficial in the detection of early stage disease.   
Limitations 
 This study has several methodological limitations that may introduce bias into the results.  
The first is the use of aggregate geographic data to estimate the income and educational levels of 
study subjects.  The education and income data were obtained by geo-coding individual records 
contained in the SEER-Medicare database and then linked to socioeconomic characteristics of 
residential zip code areas obtained from census data.  Historically, aggregate proxies have often 
been used to obtain socioeconomic data where the primary data has not been collected or the 
information is missing for the analysis of health outcomes (Brinton, et al. 1990a, Parazzini, et al. 
1993, Madeleine, et al. 1997, Sherman, et al. 1994).  The ability to utilize proxies to obtain 
socio-economic information may introduce misclassification into the study but it provides a 
method to control for potential confounding of missing information. 
 Second is the use of an OIP and PIDP framework to estimate the average durations of 
occult invasive and pre-invasive detectable phases of vaginal and vulvar cancers.    The 
121 
 
OIP/PIDP model parameters were originally developed by utilizing a study population that 
included women from all age groups who were diagnosed with cervical cancer (Weiss, 1999).  
This study, however, exclusively focuses on a population of women at or over the age of 65 who 
were diagnosed with vaginal or vulvar cancers. 
 Third the data used for the study was obtained between the years 1991 and 1999 and 
needs to be updated.   
Conclusion 
 The findings of this study suggest that Pap smear and pelvic examination screenings 
reduce the risk of late stage invasive vaginal and vulvar cancers.  Gynecological screenings 
reduce the risk of vulvar cancer among women aged 65 to 74 years old and late stage vaginal and 
vulvar cancers in women aged 65 and over.  Late stage vaginal and vulvar cancers have lower 5-
year survival rates than early stage disease.  The development of late stage disease has high 
disability rates (especially among older women with co-morbid conditions).  Thus, continuation 
of gynecological screenings among Medicare recipients may reduce the risk of late stage disease 
from early detection of VIN and VAIN and early stage disease.  Screening policy 
recommendations by professional and governmental organizations should support screening 
efforts in women over a lifetime from menarche.   
 The study recommends that older women be screened upon entering the Medicare system 
if they have not had sufficient previous screening history and subsequent to this if they have had 
three consecutive negative Pap smears.  The Patient Protection and Affordable Care Act (May 
2010), makes it possible for beneficiaries of original Medicare to qualify for a yearly wellness 
visit and many preventive services for free (Patient Protection and Affordable Care Act, 2010).  
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As of January 1, 2011, cervical cancer screening, including Pap smear and pelvic examination, is 
available without the need for Medicare Part B deductible or copayment (DHHS, 2012). 
 The study further recommends that future screening studies should also include the cost-
effectiveness of screening policies that extend over a lifetime.  Furthermore, the disabling effects 
of vaginal and vulvar cancer treatments can affect the quality-of-life for many women.  Since 
women depend on their physicians for recommendation, physicians should be trained to counsel 
older women, especially those with co-morbid conditions.  Future studies should also include the 
psycho-social and cultural aspects of cancer treatments in older women. 
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